{
  "name" : "dacemirror.sci-hub.se_journal-article_4ddc1aecc8425c02d9e3508dcc9f7a48_fu2018.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Photoacoustic Imaging: Contrast Agents and Their Biomedical Applications",
    "authors" : [ "Qinrui Fu", "Rong Zhu", "Jibin Song", "Huanghao Yang", "Xiaoyuan Chen" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "REVIEW\n1805875 (1 of 31) © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.advmat.de\nPhotoacoustic Imaging: Contrast Agents and Their Biomedical Applications\nQinrui Fu, Rong Zhu, Jibin Song,* Huanghao Yang,* and Xiaoyuan Chen*\nDOI: 10.1002/adma.201805875\nis caused by absorbed light energy, creating a broadband US wave that can be detected by a US transducer, converted to electric signals that are duly processed to get a PA image. PA imaging is a noninvasive imaging strategy that depends on the light-absorption coefficient of the imaged tissue. Since the PA signal varies according to the distribution of light absorption in biological tissue, therefore, PA imaging is similar to optical imaging, which achieves a high imaging contrast and is sensitive to the tissue characteristics. However, the carrier of the light-absorption information is not an optical signal but rather a US wave signal processed to obtain an image, with the merits of negligible scattering and dissipation in biological tissue. Therefore, PA imaging integrates the excellent contrast achieved in optical biomedical imaging with the deep penetrability of US imaging.[9] Thus, PA imaging can be used for the imaging of deeper tissue compared to other optical imaging technologies.[10,11] However, in comparison with US imaging, the light intensity and PA signal-to-noise ratio exhibit exponential\nattenuation with increasing tissue depth due to the strong laserscattering effect. To improve the PA-imaging contrast, resolution, and penetrability to tissue, externally injected PA-imaging contrast agents with high PA-imaging property in the tissue need to be developed.[12–15]\nIn PA imaging based on contrast agents, the optical energy of a pulse laser is absorbed by PA contrast agents and subsequent converted to thermal energy with an increase of temperature. The instantaneous temperature rise results in thermoelastic expansion and subsequent ultrasonic emission that can be detected by employing a US transducer to reconstruct the PA image. Overall, the PA-imaging contrast mainly rests with optical absorbance and thermoacoustic conversion efficiency, since the generated PA signal amplitude is proportional to the light absorption and the thermoelastic performances of the absorbing agent. To further improve the PA imaging quality, various PA imaging modalities and agents have been explored to enhance the PA signal.[16–23] Commonly used contrast agents for PA imaging include endogenous chromophores, such as melanin,[24] oxyhemoglobin/deoxyhemoglobin,[25] lipids,[26] or collagen,[27] as well as exogenous contrast agents (henceforth referred to as contrast agents). Such agents are required to diagnose and treat diseases such as breast carcinoma or glioma,\nPhotoacoustic (PA) imaging as a fast-developing imaging technique has great potential in biomedical and clinical applications. It is a noninvasive imaging modality that depends on the light-absorption coefficient of the imaged tissue and the injected PA-imaging contrast agents. Furthermore, PA imaging provides superb contrast, super spatial resolution, and high penetrability and sensitivity to tissue functional characteristics by detecting the acoustic wave to construct PA images. In recent years, a series of PA-imaging contrast agents are developed to improve the PA-imaging performance in biomedical applications. Here, recent progress of PA contrast agents and their biomedical applications are outlined. PA contrast agents are classified according to their components and function, and gold nanocrystals, gold-nanocrystal assembly, transition-metal chalcogenides/MXene-based nanomaterials, carbon-based nanomaterials, other inorganic imaging agents, small organic molecules, semiconducting polymer nanoparticles, and nonlinear PA-imaging contrast agents are discussed. The applications of PA contrast agents as biosensors (in the sensing of metal ions, pH, enzymes, temperature, hypoxia, reactive oxygen species, and reactive nitrogen species) and in bioimaging (lymph nodes, vasculature, tumors, and brain tissue) are discussed in detail. Finally, an outlook on the future research and investigation of PA-imaging contrast agents and their significance in biomedical research is presented.\nPhotoacoustic Imaging\nQ. Fu, R. Zhu, Prof. J. Song, Prof. H. Yang MOE Key Laboratory for Analytical Science of Food Safety and Biology College of Chemistry Fuzhou University Fuzhou 350108, China E-mail: jibin.song@nih.gov; hhyang@fzu.edu.cn Prof. X. Chen Laboratory of Molecular Imaging and Nanomedicine (LOMIN) National Institute of Biomedical Imaging and Bioengineering (NIBIB) National Institutes of Health (NIH) Bethesda, MD 20892, USA E-mail: shawn.chen@nih.gov\nThe ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/adma.201805875."
    }, {
      "heading" : "1. Introduction",
      "text" : "Photoacoustic (PA) imaging is a promising biomedical imaging modality that exhibits the superb contrast of traditional optical imaging with the outstanding spatiotemporal resolution of ultrasound (US) imaging.[1–6] PA imaging exploits the PA effect[7] that was first reported by Alexander Graham Bell.[8] Briefly, an instant thermoelastic expansion of a tissue structure\nAdv. Mater. 2019, 31, 1805875\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (2 of 31)\nbecause the diseases do not generate endogenous contrast agents and are therefore difficult to detect via PA imaging. Contrast agents for PA imaging reinforce the image contrast ratio and enhance the resolution by altering the optical and acoustic properties of local tissue, thus remarkably improving the image output. An excellent contrast agent should possess the photophysical properties of low quantum yield, high molar-extinction coefficient, near-infrared (NIR) window peak absorption, and excellent photostability as well as having low toxicity and immunogenicity, high target affinity and specificity, and high biocompatibility.[17] To date, a wide variety of contrast agents for PA imaging have been reported, including gold nanocrystals,[28] carbon nanotubes,[29,30] graphene-based agents,[31] 2D graphene analogues,[32] organic nanoparticles,[33,34] and semiconducting polymer nanoparticles (SPNs),[35–40] among others. Nevertheless, given their importance in the early diagnosis, treatment, and monitoring of various diseases, assessment of tissue morphological structure, metabolism and physiological function, and pathological characteristics, much work is ongoing in this area.[10,12,15,41] To date, PA imaging has been applied in the biological sensing of metal ions, pH, enzymes, temperature, hypoxia, reactive oxygen species (ROS), and reactive nitrogen species (RNS), as well as in the imaging of tumors, lymph nodes (LNs), vasculature, and brain tissue.[10,42–48]\nHere, we focus on the developments of PA contrast agents and their biomedical applications in recent years (Figure 1). First, we provide a comprehensive summary and review of the available contrast agents, including gold nanocrystals, gold-nanocrystal assembly, transition-metal chalcogenides/ MXene-based nanomaterials, carbon-based nanomaterials, other inorganic imaging agents, small organic molecules, semiconducting polymer nanoparticles, and nonlinear PA-imaging contrast agents. These contrast agents are highly effective and\nenable PA imaging with desired contrast and superb spatial resolution. We then focus on the recent development in the biomedical applications of PA-imaging contrast agents, including biosensing of metal ions, pH, reactive oxygen species, reactive nitrogen species, enzymes, temperature, and hypoxia, as well as in the bioimaging of tumors, lymph nodes, vasculature, and brain function (Table 1). Finally, the future paths in the research and development of PA imaging and its contrast agents are discussed.\nJibin Song obtained his Ph.D. degree in chemical and biomedical engineering at Nanyang Technological University, Singapore, in 2014. He then worked with Prof. Xiaoyuan (Shawn) Chen as a postdoctoral fellow at the National Institutes of Health (NIH). He joined Fuzhou University as a Min Jiang Scholar Professor of analytical\nchemistry in 2018. His research focuses on developing molecular-imaging nanoprobes for bioimaging, biosensing, and drug/gene delivery.\nHuanghao Yang received his Ph.D. from Xiamen University in 2002 and then carried out postdoctoral research at Hong Kong University of Science and Technology (2002–2004). He joined Fuzhou University in 2008 as a Min Jiang Scholar Professor. His research interests mostly focus on nanotechnology and cancer therapy.\nXiaoyuan (Shawn) Chen received his Ph.D. in chemistry from the University of Idaho in 1999. He joined the University of Southern California as an assistant professor of radiology in 2002. He then moved to Stanford University in 2004 and was promoted to associate professor in 2008. In 2009, he joined the Intramural\nResearch Program of the NIBIB/NIH as a Senior Investigator and Chief of the Laboratory of Molecular Imaging and Nanomedicine (LOMIN).\nAdv. Mater. 2019, 31, 1805875\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (3 of 31)"
    }, {
      "heading" : "2. Inorganic Contrast Agents",
      "text" : ""
    }, {
      "heading" : "2.1. Metallic Nanomaterials",
      "text" : "Localized surface plasmon resonance (LSPR) is the plasmonic resonant oscillation of the free conduction electrons at the interface between positive and negative permittivity metallic nanomaterial illuminated by incident light. Metallic nanomaterials possess excellent light absorption and exceptional photothermal conversion ability due to the LSPR effect. Thus, metallic nanomaterials are employed in PA imaging via excellent light absorption property and cancer treatment through the conversion of plasmon resonance into heat. Given the above properties, metallic nanomaterials are also effective as contrast agents for PA imaging as well as imaging-guided photothermal therapy (PTT). Herein, we will further review three types of metallic nanomaterials, namely: (1) gold nanocrystals and (2) their assemblies, and (3) transition-metal chalcogenides/ MXene-based nanomaterials."
    }, {
      "heading" : "2.1.1. Gold Nanocrystals",
      "text" : "Gold nanoparticles (AuNPs) have long been generally employed as PA-imaging contrast agents due to the LSPR effect, which allows their adjustable and excellent optical absorption.[28,49–55] In addition, AuNPs can attain high photothermal conversion effect upon laser illumination[56,57] and are highly biocompatible, have good chemical inertness, excellent physiochemical properties, and a high extinction coefficient.[58,59] AuNPs have been synthesized as nanorods,[60–66] nanoprisms,[67,68] nanocages,[53,69–74] nanospheres,[75–78] nanostars,[79–83] nanodisks,[84–86] bipyramids and rhombic dodecahedra,[87] nanoplates,[51,88,89] nanoshells,[90–93] nanotripods,[94] and nanowreaths.[95]\nWhen the particle size, interparticle distance, and morphological characteristics of AuNPs are changed, the relative range of absorbed and scattered light can be adjusted, thereby facilitating PA-imaging contrast. For example, the optical absorption of gold nanospheres (AuNSp; Figure 2A) and blood are both at ≈520 nm,[96] making it difficult to differentiate between the PA signals of AuNSp and blood. Fortunately, the LSPR peaks can be adjusted to the NIR region by regulating the structure, size, and sharpness of AuNSp. For example, Li and co-workers developed poly(ethylene glycol)coated (PEGylated) hollow AuNSp of 40–50 nm in size, with\na tunable absorption peak at 800 nm.[77] Importantly, the PA signal of PEGylated hollow AuNSp is much stronger than that of blood.\nGold nanorods (AuNRs) (Figure 2B) possess a cylindershaped structure that affects the absorbance band, wherein absorbance shifts further toward the NIR region with the increase in particle aspect (length to width) ratio. Therefore, due to their simple synthesis and adjustable NIR absorption behavior, AuNRs play an important role in the field of PA contrast agents.[60,97] For example, Gambhir’s group synthesized AuNRs with higher aspect ratios to achieve an increased PA signal;[60] compared with AuNRs with an aspect ratio of 2.4 and 2.9, those with the aspect ratio of 3.5 exhibited the strongest ex vivo and in vivo PA imaging performance. Additionally, AuNRs can be easily encapsulated in silica NP to form silica-coated AuNPs, facilitating cellular uptake and increasing the PA intensity of AuNRs.[98]\nFurthermore, gold-based hybrid bimetallic nanorods are useful contrast agents for PA imaging as well as therapeutic agents for bacterial infections. Au/Ag hybrid nanoagents produced by coating AuNRs with Ag showed a decreased PA signal compared with the uncoated counterparts.[99] Interestingly, Agcoated AuNRs were shown to be stable under ambient conditions, yet the Ag shell can be etched through the addition of a ferricyanide solution. The PA intensity is simultaneously enhanced as the Ag+ is etched, with the localized release of Ag+ being monitored by the PA signal.\nGold nanoprisms (AuNPrs) (Figure 2C) are anisotropic and display an LSPR band in the NIR region, with potential as contrast agents for PA imaging. Bao et al. successfully prepared PEGylated AuNPrs with excellent biocompatibility and an LSPR band mainly localized at 830 nm, a suitable wavelength for PA contrast agents.[100] The wavelength was further redshifted by conjugating a cyclic Arg-Gly-Asp (cRGD) peptide onto the PEGylated AuNPrs, leading to an LSPR peak at 980 nm; these AuNPrs were confirmed to be highly efficient PA contrast agents for tumor imaging.[67]\nGold nanocages (AuNCs) (Figure 2D) are cubic nanoparticles (NPs) with a hollow nanostructure and an absorption band ranged from 600 to 1200 nm, which can serve as excellent PA contrast agents for biomedical applications.[70] For example, Tao and co-workers developed AuNCs-based nanoagents to target LNs, with the procedure being monitored in real time by PA imaging.[69] Furthermore, AuNCs were prepared through an ultrafast technique using a microwave-oven heating method,\nAdv. Mater. 2019, 31, 1805875\nTable 1. PA contrast agents and their bioapplications.\nPA contrast agents\nMetallic nanomaterials Gold nanocrystals, gold-nanocrystal assemblies, Ag nanocrystals, Pd nanosheets, copper neodecanoate NPs\nTransition-metal chalcogenides/MXene-based nanomaterials WS2, TiS2, Ag2S, CuS, CuInS/ZnS, Ti3C2, Nb2C, TaC, MoSe2, CoS2, ReS2, Bi2S3, VS2\nCarbon-based nanomaterials SWCNT-cRGD, Au-coated SWCNTs, CNTR@AuNPs, rGO-AuNR, rGO-AuNRVe\nOther inorganic imaging agents Fe3O4, MoOx, Te, B, BP, Fe@gamma-Fe2O3@TiO2, Cu-Ag2S, MnOx/Ti3C2, CuS@Cu2S@Au\nSmall organic molecules Porphyrin, melanin, cyanine-based dye, perylene-diimide, porphysomes\nSemiconducting polymer nanoparticles semiconducting polymers and oligomers\nBioapplications Biosensing Metal ions, pH, ROS, RNS, Enzymes, temperature, hypoxia\nBioimaging Tumors, LNs, vasculature, brain function\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (4 of 31)\nand they were also used in the diagnosis and treatment of ocular diseases by PA imaging.[101]\nGold nanostars (AuNSt) (Figure 2E), with a star-shaped nanoconformation, have plasmon bands that are tunable into the NIR region. The plasmon resonance wavelength of AuNSt correlates with the branch aspect ratio, and the band intensity increases with increasing number of branches, the length of the branches, and the overall star size.[102] Therefore, AuNSt are another kind of PA contrast agents. For example, spiky Fe3O4@Au nanostars with preeminent biocompatibility, prepared through a seed-mediated growth method, were applied in multimodal MRI/Raman/PA imaging-guided PTT and photodynamic therapy.[79]\nGold-based nanoplates (Figure 2F) are 2D nanomaterials with a tunable LSPR in the NIR region, and they can also be explored as PA-imaging agents. For example, Zheng and coworkers fabricated PEGylated core–shell Pd@Au nanoplates through a seeded growth approach.[51] The PEGylated Pd@ Au nanoplates exhibited outstanding stability and high tumor uptake efficiency, as well as a high PA signal in the tumor. Therefore, the nanoplates are excellent PA-imaging contrast agents. The use of gold nanodisks (Figure 2G) in PA imaging\nis rarely reported; however, 2D nanodisks can also be considered as nanoplates in a broader sense. Lee and co-workers synthesized 2D gold nanodisks through a physical synthesis method.[84] The stacked Au nanodisks possessed intrinsic optical merits in a whole range of resonant wavelengths and a superior light-response ability, and could therefore be employed as sensitive contrast agents for PA imaging.\nThe LSPR frequency of gold nanoshells (AuNSh) can be easily tuned through tailoring their size or shell thickness, with thinner shells leading to a redshift.[103] A tunable characteristic peak wavelength is therefore highly advantageous for PA imaging. Chen and co-workers prepared branched nanoporous AuNSh (BAuNSP) through a one-step, seedless method (Figure 2H).[90] The LSPR peak wavelength of BAuNSP was further redshifted to the NIR region compared with AuNSh due to intense plasmon coupling in the shell nanopores and the surface plasmon between the outer and inner shells, with great potential for PA imaging and biomedical applications. Unsurprisingly, an aqueous BAuNSP solution showed a stronger PA signal than an aqueous AuNSh solution with the same optical density (OD). In addition, the accumulation behavior of BAuNSP in the tumor was monitored by PA imaging.\nAdv. Mater. 2019, 31, 1805875\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (5 of 31)\nAnisotropic hybrid gold NPs have shown outstanding optical and physical properties compared with their isotropic structural counterparts. As representative anisotropic nanomaterials, AuNRs and AuNCs have shown great promise as PA-imaging contrast agents; however, the size of the particles is relatively large (≈50 nm), which hinders their penetration into the tumor site and seriously impedes their potential application for targeted tumor imaging.[14,72,94,104] Cheng et al. synthesized Au tripods (Figure 2I,J), with particle size less than 20 nm, a rigorous controlled morphology, excellent size distribution, and strong visible and NIR absorptions, thereby showing great advantages as PA-imaging contrast agents.[94] Furthermore, cRGD peptide-functionalized Au-tripods exhibited remarkably integrin-targeted enhancement of PA imaging effects in vitro and in vivo."
    }, {
      "heading" : "2.1.2. Gold-Nanocrystal Assembly",
      "text" : "Plasmonic coupling between gold nanocrystals induces an intense electromagnetic field, improving their optical properties and photothermal conversion efficiency. Therefore, plasmonic assemblies show outstanding interparticle plasmonic coupling ability resulting in redshift of LSPR absorption band into the NIR region.[105,106] Bai et al. reported a contrast agent composed of hollow AuNSp cores and superparamagnetic iron oxide (Fe3O4) NPs satellites, with enhanced NIR absorption and magnetic properties.[107] The plasmon resonance peaks for hollow AuNSp were observed at around 800 nm, with a redshift to 830 nm following assembly with Fe3O4 NPs.\nIn recent years, plasmonic nanocrystal-based assemblies have become a significant research focus. Self-assembly offers a feasible approach to integrate discrete NPs into functional components with the potential to meet the needs of largescale material fabrication for biomedical applications.[108,109] For example, Duan and Song et al. synthesized gold nanovesicles of amphiphilic AuNPs grafted with mixed hydrophilic and hydrophobic polymers (Figure 3A).[110–112] In these studies, the amphiphilic AuNPs were assembled into vesicles through a self-assembly film rehydration method. Closely packed AuNP films were formed via the slow evaporation of chloroform (a common organic solvent), which provided an advantageous state of energy for the hydrophilic and hydrophobic homopolymers, such that the separated thin films could be rolled to form vesicles after rehydration. The shell layer of the as-prepared vesicles was shown to be a monolayer array composed of tightly bonded AuNPs (Figure 3B,C). Figure 3A illustrates the fabrication process, showing the hydrophobic brushes collapse to form the vesicle shell and the hydrophilic brushes rearrange in conformation; furthermore, the AuNPs are embedded within the shell. In further work, Chen and co-workers developed biodegradable plasmonic gold nanovesicles of AuNPs coated with block copolymer of PEG-PCL for PA imaging.[113] This technique achieved dense packing of AuNPs in the vesicular shell, leading to enhanced plasmonic coupling properties between adjacent AuNPs and inducing an enhanced NIR absorption suitable for PA imaging.\nIt is well known that gold has good biocompatibility, yet AuNPs exert size-dependent biotoxicity. It was reported that\nAuNPs with a core size of 8–37 nm can cause serious disease in animals, yet AuNPs with size smaller than 8 nm do not.[114] Thus, the self-assembly of AuNPs with smaller size (less than 8 nm in diameter) would be of great practical significance. Deng et al. synthesized gold nanomicelles (AuNMs) via the self-assembly of comb-like amphiphilic polymers and AuNPs of 6 nm in size,[115] which was further employed as nanoplatform to load the anticancer drug doxorubicin (DOX) (Figure 3D). The AuNMs (Figure 3E) exhibited excellent biocompatibility and no potential toxicity to multiple cell types, such as murine fibroblasts (L929) cells, MCF-7 cells, and human umbilical vein endothelial cells (HUVECs), and have the potential to be utilized as a highly effective PA contrast agent. Additionally, the wavelength of densely packed AuNMs with short AuNP chain assemblies showed a remarkable redshift compared to the individual AuNPs and AuNP chains, which is good for biomedical imaging (Figure 3F).\nDespite the great potential of discrete AuNRs as PA-imaging contrast agents as described in Section 2.1.1, AuNRs have an inherent defect, wherein those with a length of over 40 nm have a slow clearance rate from the human body. Ideally, to address this, sub-100 nm plasmonic assemblies consisting of biocompatible substances and smaller AuNRs, with outstanding tumor accumulation and rapid clearance after treatment need to be developed. Chen and co-workers synthesized small AuNR vesicles, ≈60 nm in size, assembled through PEG- and poly(lactic-co-glycolic acid) (PLGA)-coated ultrasmall AuNRs (dimension: ≈8 nm in length, 2 nm in width) via an emulsion approach (Figure 3G).[63] The biodegradable AuNR@ PEG/PLGA vesicles were hydrolyzed to form small, hydrophilic, PEG-coated AuNRs (AuNR@PEG) (Figure 3H), which are stable under physiological conditions and have a rapid clearance rate. In addition, the absorption peak of the vesicles can be adjusted in the range of 800–1050 nm by increasing the nanovesicle size. Compared with single AuNRs, strong interparticle plasmon coupling between the AuNR vesicles resulted in an amplified PA signal (Figure 3I), with the PA intensity of the AuNR vesicle being an order of magnitude higher than that of AuNRs when treated with an 808 nm laser. The plasmon peak wavelength can also be tailored by changing the interparticle distance of AuNPs.[116] Thus, in order to further improve PA-imaging performance, the interparticle spacing within the nanovesicles must be carefully adjusted to increase their absorption wavelength in the NIR window. To address this, Nie and co-workers proposed a hierarchical self-assembly method for the synthesis of AuNP chain vesicles with an enhancement of NIR absorption and PA contrast (Figure 3J),[117] wherein the AuNP strings and networks are clearly embedded within the vesicular membranes. The obtained vesicles had a hollow structure and were composed of a monolayer of AuNP strings (Figure 3K). The small interparticle distance (≈0.8 nm) within each string of AuNP chain nanovesicles led to enhanced NIR absorption caused by the plasmonic coupling effect between contiguous AuNPs;[116] therefore, the chain nanovesicles possess a stronger maximum peak wavelength (780 nm) than that of nonchain nanovesicles (620 nm) (Figure 3J,L). For PA imaging in vivo, the chain vesicle group exhibited an eightfold increase in PA intensity compared to the control group (without PA contrast agents), whereas only a minor increase\nAdv. Mater. 2019, 31, 1805875\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (6 of 31)\nAdv. Mater. 2019, 31, 1805875\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (7 of 31)\nin PA-imaging signal was tested for the nonchain nanovesicle group.\nThe self-assembly of nanomaterials is an interdisciplinary subject involving the recomposition of ordered structure and the surface modification of materials. It is at the frontier of chemistry and material science and the cradle of new functional materials. Nanoparticle assemblies possess magnetic, electronic, and optical properties that vary considerably from those of the corresponding single NPs. For example, Chen and co-workers reported a double-layer plasmonic–magnetic nanovesicle assembly that was prepared using different hydrophilic polymer brushes functionalized onto the Au and Fe3O4 NP surfaces, respectively, forming Janus amphiphilic AuFe3O4 NPs.[118] The location of the Fe3O4 and Au NPs within the vesicular shell could be easily exchanged by adjusting the amphiphilicity of the conjugated polymer brushes (Figure 3M). Subsequently, the double-layered vesicle with an Fe3O4 NP outer shell (DL-Ve2) opposite to the Au NP outer shell doublelayered vesicle (DL-Ve1) was prepared accordingly by varying the amphiphilicity of Au or Fe3O4 NPs (Figure 3N). In addition, the DL-Ve2 vesicles displayed a distinct increase in magnetic and optical properties because of the enhanced plasmonic coup ling effect between the Au NPs and magnetic dipole interactions of Fe3O4 in the double-layered vesicle. Specifically, the PA intensity of DL-Ve2 was 5- and 2.2-fold higher than that of a monolayer vesicle and DL-Ve1, respectively, at the same OD785 (Figure 3O).\nApart from Au nanocrystals, other metal nanomaterials such as Ag nanocrystals,[119–121] Pd nanosheets,[122–125] and copper\nneodecanoate NPs[126] have also been explored to serve as contrast agents for PA imaging."
    }, {
      "heading" : "2.1.3. Transition-Metal Chalcogenides/MXene-Based Nanomaterials",
      "text" : "In addition to Au nanocrystals and their assemblies, transitionmetal chalcogenides/MXene-based nanomaterials have also been widely used as PA-imaging agents.[127–137] For example, Cheng et al. designed PEGylated tungsten disulfide (WS2-PEG) (Figure 4A) that could act as a PA-imaging contrast agent of tumors, as well as being a highly effective photothermal agent due to its excellent NIR absorbance.[138] TiS2 (a transition-metal dichalcogenide) nanosheets (Figure 4B) exhibited high physiological stability, negligible toxicity, and high absorbance intensity in the NIR window. TiS2 nanosheets have been used as a PTT agent to guide tumor ablation with PA imaging in vivo, with excellent therapeutic effect being observed in a mouse tumor model.[139] Zhao and co-workers reported a nanoagent with excellent targeting capability and PA contrast using folic-acid-modified Pluronic F127, encapsulated in oil-soluble Ag2S quantum dots (Figure 4C).[140] The nanoagent has been employed as an excellent PA-imaging agent of HeLa tumor cells, which have a high expression of the folate receptor. CuS NPs have also been extensively used as PA contrast agents (Figure 4D).[133,141–143] For example, Yang et al. designed a CuSbased PA agent (CuS-peptide-BHQ3) (CPQ)) for in vivo matrixmetalloproteinase sensing.[144] As a combination, two different\nAdv. Mater. 2019, 31, 1805875\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (8 of 31)\ntransition-metal chalcogenides can also serve as PA-imaging contrast agents; for example, Liang and co-workers developed a multifunctional theranostic contrast agent using CuInS/ ZnS quantum dots (Figure 4E), which have good therapeutic potential.[145]\nTransition-metal MXene-based nanomaterials have also received increasing attention as contrast agents for PA imaging recently. For example, Yang and co-workers designed a type of 2D MXene-based nanoagent, Ti3C2@mMSNs (Figure 4F), consisting of Ti3C2 MXene nanoparticles coated with a thin shell of mesoporous silica.[146] An enhanced contrast agent was further developed using this system by grafting with a cRGD sequence, Ti3C2@mMSNs-cRGD, providing sensitive imaging-guided and real-time monitoring of tumors. Shi and co-workers fabricated a 2D Nb2C MXene to serve as a PA-imaging contrast and phototherapeutic agent, which could be used in tumor photothermal ablation.[147] Following surface functionalization with poly(vinylpyrrolidone) (PVP), the as-prepared Nb2C-PVP nanoagent showed enzyme-responsive biodegradability and excellent biocompatibility to myeloperoxidase, as well as insignificant phototoxicity and superb physiological stability."
    }, {
      "heading" : "2.2. Carbon-Based Nanomaterials",
      "text" : "Two main categories of carbon-based nanomaterials, namely, carbon nanotubes (CNTs)[29,30,148–151] and graphene-based nanomaterials,[31,32,52,152–159] have been extensively investigated as contrast agents. Both categories have a distinct absorption in the NIR window. Despite their lower molar-extinction coefficient compared to gold nanocrystals, carbon-based nanomaterials are promising for PA imaging due to their ease of fabrication and functionalization. Nonplasmonic single-walled CNTs (SWCNTs) have a wide-band absorption, including the NIR window, providing an enhanced PA signal.[160] However, they have no specific peak in the wide-band absorption spectrum, which impedes their application in absorptionwavelength-dependent PA imaging. Fortunately, the PA intensity could be further improved by integrating plasmonic metal nanomaterials or small molecules into carbon-based nanomaterials.[160–164] For example, de la Zerda et al. developed cRGDfunctionalized SWCNTs (SWCNT-cRGD) that were used in the PA imaging of tumors, exhibiting an eight times higher of the PA signal of the tumor section compared with plain SWCNTs.[160] The PA signal of the SWCNT-cRGD was then further increased through coating ICG dye onto the surface of SWCNTs;[165] the SWCNT-ICG exhibited a 20-fold higher optical absorbance at 780 nm compared with plain SWCNTs and was bound to live animal molecular targets while maintaining a high PA contrast. A further study coating SWCNTs with either QSY21 (an optical dye and quencher) or ICG dye showed a 17- and 20-fold increase in the particles’ absorption and an over 100-fold stronger PA intensity compared with plain SWCNTs.[161] In another example, Chen and co-workers used hyaluronic acid-5β-cholanic acid conjugated with folic acid to modify hydrophobic SWCNT, achieving high tumor-uptake efficiency of the SWCNT. PA imaging was further used to trace the circulation and tumor uptake of the functionalized SWCNT in vivo.[166]\nNoble-metal NP-coated SWCNTs possess an increased NIR absorption, enhanced biocompatibility, and excellent PAimaging capability.[167–171] For example, Kim et al. developed Aucoated (4–8 nm layer) SWCNTs (GNTs) with a size of 1.5–2 nm (Figure 5A);[170] the absorbance intensity of the GNTs was over 85 times higher than that of SWCNTs in the NIR window at the same concentration. Furthermore, lymphatic endothelial hyaluronan receptor-1 (LYVE-1)-antibody-conjugated GNTs have been employed in dual-mode PA and photothermal imaging of lymphatic endothelial receptors (Figure 5B). In another example, Chen and co-workers prepared a class of contrast agent that was based on CNT rings (CNTRs) coated with AuNPs (CNTR@AuNPs) by growing AuNPs on the surface of CNTRs (Figure 5C).[169] Due to the plasmonic coupling of the AuNPs, the LSPR peak of the CNTR@AuNPs (Figure 5D) redshifted with the increase of AuNP size (Figure 5E). In addition, compared with AuNP-coated non-ring-CNTs (CNT@AuNPs) and whole Au-nanoshell-coated CNTRs (CNTR@AuNS), the CNTR@AuNPs had significantly higher photothermal conversion efficiency. The PA amplitude of CNTR@AuNPs was also remarkably higher than that of CNTRs, CNTR@AuNSs, and CNT@AuNPs (Figure 5F).\nGraphene-based nanomaterials are another commonly used class of carbon-based nanomaterial for PA imaging,[159,172,173] extensively studied in the biomedical field because of their unique chemical and physical properties.[174] Compared with CNTs, graphene-based nanomaterials, especially reduced graphene oxide (rGO), possess a larger surface area and better dispersibility in most biological conditions. Recently, rGOcoated AuNPs were reported to have an enhanced PA signal, wherein the plasmonic AuNPs can act as a local nanoantenna to increase the optical absorption efficiency of rGO. The interaction of plasmonic AuNPs and rGO under laser illumination leads to the enhanced photocurrent of rGO, thus improving its photothermal properties; such systems are promising PA contrast agents.[169,175] Lim and co-workers designed a PA contrast agent consisting of rGO-coated AuNRs (rGO-AuNR) with strong NIR absorption, good photothermal stability, and enhanced PA amplitudes[176] (Figure 5G–I). The rGO layer provides thermal conductivity, leading to highly efficient heat transfer. Thus, the light-absorbing properties of rGO can be further enhanced by AuNRs. Chen and co-workers designed a hybrid rGO-loaded AuNR vesicle (rGO-AuNRVe) through a double-emulsion technique to integrate PEGylated rGO into AuNR vesicles of amphiphilic small AuNRs grafted with PEG and PLGA, for continuous drug release and increased photothermal and PA effects[177] (Figure 5J,K). Compared with the mixture of AuNRVe and rGO, the rGO-AuNRVe showed a stronger PA intensity of the same OD808 value (Figure 5L), with the PA intensity of the mixture being ≈2.5-fold lower than that of the rGO-AuNRVe.\nThe above examples show that the assembly of AuNPs not only gives rise to the redshift of their maximum absorption band from the visible region to the NIR window by shortening the interparticle space, but also enhances the photothermal conversion capability due to the intense plasmonic coupling prosperity between adjacent AuNPs. A series of carbon-based nanomaterials of graphene, CNT, and their assemblies with AuNPs were also developed and functionalized to investigate\nAdv. Mater. 2019, 31, 1805875\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (9 of 31)\ntheir optical properties.[178] The obtained assembled nanostructures exhibit dual enhanced photothermal conversion characteristics of optically triggered acoustics and thermal treatment. Therefore, AuNP assemblies and hybrid carbon-based nanomaterials can serve as promising nanoagents for sensitive in vivo PA imaging."
    }, {
      "heading" : "2.3. Other Inorganic Imaging Agents",
      "text" : "In addition to the abovementioned nanomaterials, researchers have also reported various other nanomaterial-based PAimaging contrast agents, such as tellurium nanosheets,[179] boron nanosheets,[180] black-phosphorus nanosheets,[181] black-phosphorus quantum dots,[182] tantalum carbide nanosheets,[183] molybdenum selenide,[184] cobalt sulfide nanosheets,[185] rhenium disulfide nanosheets,[186] bismuthsulfide-based NPs,[187,188] and vanadium disulfide nanostructures,[189] as well as nanohybrids such as Fe@gamma-Fe2O3@ TiO2 nanocomposites,[190] Cu-Ag2S NPs,[191] tantalum carbide (Ta4C3)-based composite nanosheets,[192] Ti3C2-based composites (MnOx/Ti3C2),[193] and CuS@Cu2S@Au nanohybrids.[194] For example, Chen and co-workers developed a highly versatile Fe3O4@polydopamine core–shell nanocomposite system with an Fe3O4 core and a thin polydopamine shell, which can be utilized for intracellular mRNA sensing and dual PA and MRI-imaging-guided PTT.[195] Thawani et al.[196] fabricated an indocyanine green (ICG)-coated superparamagnetic iron oxide\nAdv. Mater. 2019, 31, 1805875\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (10 of 31)\nNP cluster, which was employed for PA-imaging-guided braintumor surgery in mice. In another example, Liu and co-workers designed MoOx-PEG nanosheets, which showed strong NIR absorbance[197] and a pH-dependent degradation behavior in acidic environment, and they decomposed under a physiological environment. In addition, MoOx-PEG is a strong PAimaging contrast, and therefore its degradation in vivo can be monitored with PA imaging."
    }, {
      "heading" : "3. Organic Contrast Agents",
      "text" : ""
    }, {
      "heading" : "3.1. Small Organic Molecules",
      "text" : "Organic molecular PA contrast agents, including porphyrin,[198–200] melanin,[201–203] cyanine-based dyes,[204,205] and perylene-diimide (PDI),[206–215] have been widely applied in PA imaging due to their excellent biodegradability and biocompatibility. In 2011, Zheng and co-workers developed porphysomes by combining porphyrin with phospholipids and integrating porphyrin–phospholipids into nanovesicles via a self-assembly approach.[216] Porphysomes are composed of dense porphyrin bilayers, which produce a strong self-quenching effect through intermolecular interactions, resulting in strong nonradiative heat and thus enhanced PA signals. Further, porphyrin– lipid complexes possess excellent metal-ion-chelating ability, adjustable NIR absorption, and remarkable biodegradability (Figure 6A). Subsequently, they developed porphyrin-shell microbubbles as a dual-modality US and PA contrast agent.[217] In 2015, the Zheng group further developed trimodality contrast agents for US, PA, and fluorescence imaging, denoted as porphyrin microbubbles (Figure 6B), including a bacteriochlorophyll–lipid shell and encapsulated perfluorocarbon gas.[218] Porphyrin microbubbles burst into smaller NPs with analogous optical properties upon sonication, which can accumulate in the tumor region and thus improve the imaging quality. In addition, Zemp and co-workers developed porphyrincontaining nanodroplets with a size of ≈200 nm and excellent optical absorption, offering remarkable PA contrast as assessed in tumor or chicken embryos.[219]\nMelanin is a common natural pigment with extensive NIR absorption, superb chelating performance, and excellent stability under physiological conditions, with applications in PA imaging. For example, melanin-based NPs of ≈4.5 nm were synthesized by Fan et al. and used as a PA agent.[24] Melaninbased NPs have an outstanding chelating effect with metal ions, including Fe3+ and/or 64Cu2+, and can be used in multimodal imaging (MRI/PA/PET) of tumors (Figure 6C).\nDye-based nanomaterials have been extensively investigated as PA-imaging contrast agents because of their low toxicity, good biodistribution, and easy clearance. Heptamethine cyanine, composed of two aromatic nitrogen-containing heterocycles and linked by a heptamethine chain, was the first NIR dye to be used in PA imaging.[220] ICG, which has a maximum absorption wavelength at 780 nm and low quantum yield, is a widely used dye approved for clinical application by the U.S. Food and Drug Administration (FDA). However, ICG has the disadvantages of poor light stability and degradation in water, which severely hinder its application in the biomedical field.\nTherefore, various studies have focused on the encapsulation of the dye into biocompatible polymers or other materials to form stabilized NPs.[221] For example, Sailor and co-workers found that the intensity of the PA contrast could be improved by 17 times when using mesoporous silica NPs to encapsulate ICG; the effect was ascribed to the weak thermal conductivity of the mesoporous silica coating protecting the ICG from thermal or photolytic degradation.[221] Huang and co-workers designed a PA contrast agent composed of a hydrophobic MeHg+responsive NIR cyanine dye (hCy7) and liposomes (LP-hCy7; Figure 6D).[204] LP-hCy7 has two separated NIR absorbance peaks, and the PA signals of LP-hCy7 at 860 and 690 nm are, respectively, enhanced and reduced when MeHg+ reacts with hCy7 through the Hg-promoted cyclization method (Figure 6E). Therefore, LP-hCy7 can act as a ratiometric PA-imaging agent for the detection of MeHg+. Ratiometric imaging can provide a feasible method for relative quantification of biometric substances both in vitro and in vivo with lower influence from environmental factors that affect PA signals. However, singlewavelength contrast agents, with one intensity-dependent PA signal readout, lead to inaccurate imaging and sensing results because diverse analyte-independent factors can affect their absolute PA-signal intensity.\nFurthermore, the combination of two NIR dye types leads to greatly enhanced stability and specific new functions. Liu and co-workers developed a chemically crosslinked albumin– dye nanocomplex (C-HSA-BOPx-IR825) contrast agent, which is composed of a built-in pH indicator of the pH-responsive dye benzo[a]phenoxazine (BPOx), an encapsulated reference of the pH-inert dye IR825, and human serum albumin (HSA) (Figure 6F).[222] The C-HSA-BOPx-IR825 NP was employed to test the pH in the tumor region by both ratiometric PA and fluorescence imaging. Other NIR dyes, including naphthalocyanines,[223] phthalocyanine,[224] croconine,[225] squaraine,[226] and Prussian blue,[227,228] can also serve as PA contrast agents."
    }, {
      "heading" : "3.2. Semiconducting Polymer Nanoparticles",
      "text" : "SPNs are composed entirely of organic components, including semiconducting polymers (SP) and oligomers. SPNs have superb optical properties, such as a large absorption coefficient, adjustable optical absorption, controllable size, and high photostability, and can therefore act as contrast agents for biomedical imaging. PDI (Figure 6G), as a widely used semiconducting polymer, has received considerable attention in PA imaging due to its strong NIR-light-absorption ability and excellent biocompatibility. Moreover, PDI possesses very high photothermal stability and photothermal conversion efficiency, and is easily modified.[206,210,212,229] Cheng and co-workers successfully developed an excellent contrast agent of PDI-based NIR-absorptive organic NPs for PA imaging in the tumor region of the tumorbearing mice.[206] Fan and co-workers rationally designed an efficient PA contrast agent consisting of amphiphilic PDI derivatives and cRGD-modified NIR-absorptive organic semiconducting NPs through a self-assembly method,[229] which could be used to selectively light up early thrombus in living mice (Figure 6H). Recently, Cheng and co-workers developed photosensitizer (PS)-loaded PDI PA activating nanodroplets\nAdv. Mater. 2019, 31, 1805875\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (11 of 31)\n(PS-PDI-PAnD) consisting of a PDI shell with long alky chains and a liquid perfluoropentane core.[212] The photosensitizer ZnF16Pc showed excellent compatibility at the interlayer of the core–shell nanostructure (Figure 6I,J). As shown by transmission electron microscopy (TEM), the as-prepared PS-PDI-PAnDs possessed a uniformly distributed core–shell\nAdv. Mater. 2019, 31, 1805875\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (12 of 31)\nnanostructure (Figure 6K), and these biocompatible PS-PDIPAnDs can serve as an excellent PA-imaging contrast agent. In addition, Chen and co-workers recently reported another PDIbased contrast agent that can detect the ROS level in the tumor by PA imaging.[230] In addition, chlorin dimers,[231] polypyrrole,[232,233] polylysine,[234] smart organic NPs,[235] natural humicacid-based nanoagents,[236] and tannic-acid-based assemblies[237] have also been explored as contrast agents for PA imaging.\nIt has been recently reported that SPNs can effectively convert a photon’s energy into acoustic waves, allowing the development of responsive PA-imaging probes.[35,38,39,238–248] In order to study the PA properties of different semiconducting polymers, Pu et al. systematically studied and compared the structures and properties of diketopyrrolopyrrole (DPP)based SPNs (SPN2-4) and poly(cyclopentadithiophene-altbenzothiadiazole)-based SPN (SPN1) (Figure 7A).[249] A series of DPP-based copolymers integrated into PEGylated SPNs were synthesized via a nanoprecipitation method (Figure 7A). The different backbone structures of individual SPNs led to variations in their electron donor–acceptor properties and thus in their PA intensities; for example, SPN4 showed the highest PA signal due to its corresponding structural unit having the strongest electron-donating ability (Figure 7B). Therefore, the PA intensity and photothermal conversion efficiency of SPNs are closely related to the electron donor–acceptor property of the corresponding DPP structural units. Moreover, the fabrication\nAdv. Mater. 2019, 31, 1805875\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (13 of 31)\nof SPNs through a nanoprecipitation method usually leads to the dissociation of NPs, since SPNs prepared by nanoprecipitation, encapsulating the SP within an amphiphilic block copolymer, will produce binary micelles, which easily undergo dissociation.[240,250,251] Furthermore, in the presence of proteins or other substances in vivo, amphiphilic copolymers easily leak from the NPs, resulting in alteration of the optical properties and poor biodistribution.[252,253] Pu and co-workers reported a synthetic method to prepare structurally stable SPNs through the grafting of hydrophilic PEG onto the SP backbone.[254] Thus, the semiconducting amphiphilic polymer, which has NIR absorption capacity, could self-assemble into homogeneous NPs (Figure 7C). The results showed the excellent stability of these semiconducting amphiphilic polymers prepared by the self-assembly method, superior to that of SPN1 prepared via the nanoprecipitation approach. Moreover, the PA intensity in tumors in mice, which were injected with semiconducting amphiphilic polymers, which possessed a nondissociable nanostructure and superhigh PEG density, was three times stronger than that of the original PA signal of the tumor.\nThe combination of SPNs and dyes leads to a series of superior properties. Pu and co-workers designed a degradable and activatable PA contrast agent composed of a degradable nanocarrier semiconducting oligomer (SO) amphiphile and the ROS-inert dye NIR775 via a self-assembly method,[255] which can be used for in vivo imaging of ClO− (Figure 7D). NIR775 remained intact while the semiconducting oligomer amphiphile degraded, which was caused by ClO−, giving rise to a ratiometric PA signal (Figure 7E). Nevertheless, despite their great potential in PA imaging, biodegradable contrast agents for use in PA-imaging-guided PTT are rare. Although biodegradable polymers such as polyamides and polyesters are readily available,[256] simply introducing these hydrolyzable units (esters, carbonates, amides, etc.) into the SP backbone will inevitably hinder the electron delocalization, thus affecting the optical properties of the SPNs.[257] Recently, the same group designed optically active polymer NPs with enhanced biodegradability and elevated PTT capability by integrating a vinylene bond into the SP backbone.[257] In this design, a biodegradable semiconducting polymer, poly{2,2′-[(2,5-bis(2-hexyldecyl)-3,6-dioxo2,3,5,6-tetrahydropyrrolo[3,4-c]pyrrole-1,4-diyl)-dithiophene]5,5′-diyl-alt-vinylene} (DPPV), was synthesized and converted to water-soluble NPs (SPNV) by combining the enzyme oxidation of the ethylene bonds with polymer chemistry (Figure 7F). Compared with its counterpart, SPN without any vinylene bonds (SPNT), the presence of a vinylene bond in the SPNV backbone significantly improved the mass absorption coefficient (1.3-fold) and photothermal conversion efficiency (2.4-fold). In addition, SPNs can decompose into small fragments in a biological environment rich in oxide species (Figure 7G), leading to their efficient degradation."
    }, {
      "heading" : "4. Nonlinear PA-Imaging Contrast Agents",
      "text" : "The abovementioned studies refer to linear PA imaging; in recent years, the application of multiple laser-pulse irradiation to achieve nonlinear signal enhancement has attracted increasing research interest. Nonlinear PA imaging involves\ncontinuous excitation of biological tissue by employing a dualpulse laser with a short time delay,[258] which can provide even more significant contrast and resolution than the commonly studied linear PA imaging by reversibly switching the absorption property,[259] or enhancing the thermally related Gruneisen parameter (thermal expansion coefficient).[260–266] Some preliminary work about the contrast agents for nonlinear PA imaging has been reported recently.[267,268] For example, Gao et al. designed a contrast agent including two NIR dyes of IR-820 and IR-825 for nonlinear PA imaging.[267] Zheng and co-workers reported a contrast agent of zinc-tetra(4-pyridyl)porphyrin-encapsulated AuNRs for both nonlinear and linear PA-imaging contrast enhancement.[268] Compared with linear PA imaging, the nonlinear PA imaging showed about 12-fold contrast improvements in vitro and 4-fold in vivo."
    }, {
      "heading" : "5. Biomedical Applications",
      "text" : "In recent years, PA imaging has been increasingly used in the biomedical field. PA imaging can effectively image the structure and function of biological tissue, providing essential information to study its morphological structure, physio logical characteristics, pathological characteristics, and metabolic function, especially suitable in the early sensing and treatment of cancer. Currently, PA imaging is utilized to bioimaging of lymph nodes, vasculature, tumors, and brain function. In parallel to bioimaging, PA imaging is employed in the biosensing of metal ions, pH, ROS/RNS generation in vivo, enzymes, temperature, and blood oxygen-content detection."
    }, {
      "heading" : "5.1. Sensing of Metal Ions",
      "text" : "PA imaging has been researched for sensing of heavy-metal ions, including copper (Cu2+),[269] methylmercury (MeHg+),[204] mercury(II),[270] calcium (Ca2+),[271,272] lithium (Li+),[273] and silver (Ag+).[99] For example, Chan and co-workers developed two acoustogenic PA probes (APC-1 and APC-2) for the sensing of Cu2+.[269] The APCs contain a Cu2+-responsive 2-picolinic ester unit, which coordinates Cu2+ and induces ester-bond hydrolysis. APC-2 shows two absorption peaks, at 767 and 697 nm; in the absence of Cu2+, the 2-picolinic ester unit remains unchanged and the signal at 697 nm is stronger than that of at 767 nm, leading to small PA767nm to PA697nm intensity ratio. Following hydrolysis in the presence of Cu2+, the absorption peak at 697 nm will reduce in intensity, while that at 767 nm will be enhanced; thus, the resulting PA767nm/PA697nm intensity ratio will be increased (Figure 8A). Normalization of the PA767nm to PA697nm led to a ratiometric PA turn-on response of 100.5 and 91.3 times for 10 and 1 equivalent of Cu2+, respectively (Figure 8B).\nMeHg+ is a powerful neurotoxin, damaging the human nervous system and brain. Therefore, there is a need to develop an efficient approach for MeHg+ sensing. Huang and coworkers designed a PA contrast agent (LP-hCy7) for MeHg+ sensing (Figure 6E).[204] In the presence of MeHg+, the MeHg+responsive NIR cyanine dye hCy7 is converted to hCy7′, and the absorbance signals of the contrast agent at 860 and 690 nm are\nAdv. Mater. 2019, 31, 1805875\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (14 of 31)\nenhanced and reduced, respectively, leading to an increase in the ratiometric PA intensity. The absorption signals of LP-hCy7 at 860 and 690 nm were directly and inversely proportional to the amount of MeHg+, respectively, with the ratiometric PA intensity (PA860 to PA690) being significantly enhanced in the presence of MeHg+ (Figure 8C,D). Therefore, LP-hCy7 can be used to monitor the presence of MeHg+ by ratiometric PA imaging.\nCa2+ affects almost all aspects of cellular life and it is therefore of major importance to accurately sense Ca2+ signals. Recently, Westmeyer and co-workers developed a cellpermeable, highly selective, and sensitive PA imaging probe to sense Ca2+ content.[271] Using this probe, micromolar concentrations of Ca2+ led to a major blueshift in absorbance, causing a decrease in PA intensity. Cash et al. designed a PA sensor consisting of a lithium ionophore,[273] where a Li+-selective crown ether ionophore and a chromoionophore were used to analyze Li+ concentrations in vivo.\nBimetallic nanoagents combine the inherent properties of monometallic elements, as well as exhibiting unique properties superior to those of corresponding monometallic nanoagents, thus providing a platform for the development of contrast agents with excellent selectivity, sensitivity, and stability. Ag+ is a well-known antibacterial agent, and AgNPs can serve as a reservoir of Ag+ for the targeted treatment of bacterial infections. Kim et al. developed Au/Ag hybrid NPs through the coating of AuNRs with Ag (Au/AgNRs).[99] The Au/AgNRs were inert under ambient conditions, yet upon the addition of a ferricyanide solution, the Ag shell was oxidatively etched and Ag+ was released, thus recovering the PA contrast. Simultaneously, the PA signal provided noninvasive monitoring of the localized\nrelease of Ag+, with the PA signal switching on and off with the Ag deposition and oxidation cycle on AuNRs (Figure 8E). Furthermore, the released Ag+ showed an intense bactericidal efficacy in vivo. Moreover, the PA signal in mice treated with Au/AgNRs with successive addition of Ag etchant was significantly enhanced (Figure 8F,G). The recovered PA signal suggested the localized release of Ag from Au/AgNRs and could potentially offer further critical feedback on infection diagnosis."
    }, {
      "heading" : "5.2. pH Sensing",
      "text" : "The regulation of pH plays a major role in managing homeostasis processes in mammalian tissues. Moreover, the charge state of macromolecules and proteins is also closely related to the pH, and pH variations will induce a series of pathologies, including inflammation, chronic cancer, ischemia, renal disease, and intrauterine disorders.[274–276] Therefore, pH sensing has practical significance in the design of biocompatible contrast agents to noninvasively monitor the acidity of the cancer microenvironment for better disease treatment and prognosis. Previous studies have reported preliminary pHsensing methods using PA imaging.[222,277–286] For example, Liu and co-workers successfully fabricated an albumin-based contrast agent composed of a pH-sensitive dye, BPOx, and a pH-inert NIR dye, IR825, for real-time ratiometric PA imaging of tumor pH (C-HAS-BOPx-IR825) (Figure 6F).[222] When the pH was lowered, the PA signal intensity at 680 nm was shown to increase significantly, yet, at 825 nm there was negligible change, thus providing a ratiometric PA imaging probe. The same group subsequently designed an albumin–croconine dye contrast\nAdv. Mater. 2019, 31, 1805875\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (15 of 31)\nagent for PA imaging of tumor pH.[277] In the another study, Pu and co-workers developed a smart PA nanoprobe (SONs) consisting of an inert PA matrix with a SO and a pH-indicating boron-dipyrromethene (BODIPY) dye.[278] The BODIPY dye, which contains hydroxyl groups, underwent an efficient protonation–deprotonation process in the acidic tumor environment, thus changing the absorption intensity and PA intensity of the SONs at 750 nm. Following a decrease in pH, the PA intensity at 750 nm was considerably reduced, and that at 680 nm remained intact (Figure 9A). Therefore, the PA signal ratio (PA680nm/PA750nm) can be used to sense pH in vivo. In a HeLa tumor model, the PA ratiometric intensity of SON remarkably increased at 6 h postinjection compared to that before treatment (Figure 9B).\nBecause of the intrinsic background of biological tissues, none of the abovementioned studies have demonstrated quantitative pH sensing of cancer in vivo. Lee et al. designed a quad-wavelength PA-imaging strategy to address this issue[276] (Figure 9C). Thus, the dual-wavelength ratiometric PA imaging results showed that the concentrations of SNARF-PAAm NPs and hemoglobin have a great influence on the detection of pH, and therefore the ratio of the dual-laser wavelengths is not sufficient for pH quantification. A so-called “quad-wavelength\nratiometric PA imaging method,” which is independent of blood and SNARF-PAAm NP concentration, was proposed to overcome the limitations of dual-wavelength ratiometric PA imaging (Figure 9D), with pH sensing remaining undisturbed by blood and SNARF-PAA NP concentration (Figure 9E). In vivo tumor experiments using quad-wavelength ratiometric PA imaging showed that pH levels can be quantitatively monitored, with the largest ratio emerging at 75 min postinjection (Figure 9F). Furthermore, the pH at the peripheral region (6.97) was higher than that in center of the tumor (pH 6.72), consistent with the pathological tumor mechanism (Figure 9G)."
    }, {
      "heading" : "5.3. Sensing of ROS",
      "text" : "ROS, including superoxide (O2˙−), hydrogen peroxide (H2O2), peroxyl radical (ROO˙), hydroxyl (HO˙), singlet oxygen (1O2), hypochlorous acid/hypochlorite (HOCl/−OCl), and so on, are generated by either exogenous or endogenous sources (mitochondria, inflammation, metabolic process, etc.)[287,288] and play a major role in managing many biological phenomena.[289] A high concentration of ROS is closely related to various pathological environments, including angiocardiopathy,[290]\nAdv. Mater. 2019, 31, 1805875\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (16 of 31)\natheromatosis,[291] pneumopathy,[292,293] arthronosos,[294,295] neurodegeneration,[296] and tumors or cancer.[297] Therefore, real-time PA imaging of ROS in vivo can offer essential information for the diagnosis and treatment of these diseases. Rao and co-workers developed a ratiometric PA probe consisting of poly(cyclopentadithiophene-alt-benzothiadiazole), with absorption at 700 nm, and a cyanine dye IR775S, with absorption at 820 and 735 nm, for the effective sensing of ROS in vivo.[238] IR775S was rapidly decomposed by ONOO− and ClO−, leading to a sharp decline in the peak at 820 nm while that at 700 nm remained intact; thus, the probe detected ROS levels by ratiometric (PA700nm/PA820nm) PA imaging. ClO− levels are related to various diseases and cancer; therefore, Pu and co-workers[255] similarly designed a smart PA imaging probe for the in vivo sensing of ClO− (Figure 7D). The contrast agent has two separated absorption peaks at 780 and 680 nm, and the PA signal intensity at 780 nm unchanged while that at 680 nm was gradually reduced by the addition of ClO− (Figure 7E). Thus, the ClO− level could be sensed through the variation of ratiometric PA intensity (PA780nm/PA680nm).\nH2O2 is a vital species in many physiological processes, such as immune response, cell growth, and senescence, as well as in diseases that lead to an imbalance in H2O2.[298–301] Therefore, the sensitive and precise sensing of H2O2 is of remarkable clinical significance not only for cancer treatment but also for the better understanding of pathogeny. Recently, Liu and co-workers developed a H2O2-responsive contrast agent, called Lip@HRP&ABTS, by simultaneously integrating horseradish peroxidase (HRP) and 2,2′-azino-bis(3-ethylbenzothiazoline6-sulfonic acid) (ABTS) into the liposomal NPs. ABTS reacts with H2O2 to generate its green, showing strong NIR absorbance (Figure 10A).[302] In vitro experiments showed Lipo@ HRP&ABTS to be highly specific and sensitive to H2O2 (Figure 10B). An in vivo inflammatory disease and bacterial infection model assay proved that Lipo@HRP&ABTS successfully detected H2O2 levels in vivo by PA imaging (Figure 10C). More importantly, Lipo@HRP&ABTS was also sensitive to the endogenous H2O2 response in the tumor microenvironment. In vivo PA imaging in an LN metastasis model, tumor model, and orthotopic brain glioma model (Figure 10D) was used to specifically image the tumor region according to the difference in H2O2 content by the Lipo@HRP&ABTS probe.\nMore recently, Chen and co-workers designed a PDI-based contrast agent (PDI-IR790s-Fe/Pt) with two absorption peaks at 790 and 680 nm, through a self-assembly approach.[230] In the tumor microenvironment, cisplatin was shown to be released in the presence of reductase, inducing the transformation of oxygen to superoxide free radicals, and resulting in the generation of H2O2 (Figure 10E). Fe3+ further catalyzed H2O2 to produce •OH based on the Fenton reaction. With increasing •OH content, the absorption intensity at 680 nm was stable; however, that at 790 nm gradually declined (Figure 10F), thus showing that the PDI-IR790s-Fe/Pt can function as a ratiometric PAimaging contrast agent to sense ROS levels. Furthermore, in vivo tumor ratiometric PA imaging experiments showed that the PA signal intensity at 680 nm was enhanced; however, the peak at 790 nm remained practically unchanged (Figure 10G). The corresponding ratiometric PA signals (ΔPA680/ΔPA790) in the tumor were quantitatively calculated (Figure 10H), showing\nthat PDI-IR790s-Fe/Pt NPs function as an excellent ratiometric PA contrast agent to visualize ROS in vivo."
    }, {
      "heading" : "5.4. Sensing of RNS",
      "text" : "RNS, including nitric oxide (NO) and its higher oxides, such as nitrogen dioxide radicals (NO2•), peroxynitrite (ONOO−), and nitrate (NO3−), are another type of oxidative stress-related species to cell signaling during multifarious pathological and physiological processes.[288,303] ONOO− leads to the damage of various biomolecules, including proteins, lipids, DNA, carbohydrates, and thiols, by facilitating oxidation reactions; as a result, it leads to various pathological diseases, such as inflammation and cancer, as well as cardiovascular and neurodegenerative diseases.[288] The real-time sensing of ONOO− in tumors is important for the study of the tumor etiology and select treatment methods.[304,305] Pu and co-workers designed a smart PA contrast agent with strong selective sensing of ONOO− and enhanced pH inertness, which was applied to visualize and monitor ONOO− levels in tumors of living mice via ratiometric PA imaging.[246] More recently, Chan and co-workers designed a set of acoustogenic probes for nitric oxide, termed APNOs, to sense NO in vivo[306] (Figure 11A). APNO-5 was shown to have the best performance, with a high stability, outstanding selectivity, excellent biocompatibility, and specific response to NO. APNO-5, with a maxi mum absorption band at 764 nm, was shown to react rapidly with NO to produce N-nitroso products (tAPNO-5), which have an absorption peak at 673 nm (Figure 11B,C). About 18.6-fold higher ratiometric PA signal response was observed when APNO-5 and tAPNO-5 were selectively illuminated by a laser at 770 and 680 nm, respectively (Figure 11D). When APNO-5 was converted to tAPNO-5, the PA intensity at 680 nm was enhanced whereas that at 770 nm was reduced (Figure 11E). Furthermore, APNO-5 was used in the detection of NO in an inflammation model (Figure 11F), with clear accumulation of the contrast agent being observed at the injection site. Compared to the saline control experiment, the PA was enhanced by 1.9-fold at 680 nm, and the PA680nm/PA770nm ratiometric turn-on response relative increased by 1.3 times, respectively (Figure 11G). Recently, Chan and co-workers designed NIR photo activatable NO donors that employed a direct PA readout to endow noninvasive sensing of analyte release.[307]"
    }, {
      "heading" : "5.5. Sensing of Enzymes",
      "text" : "Abnormal enzyme activity and the pathology of various diseases are strongly intertwined. Due to the major role of enzymes in many biological and physiological processes, the precise sensing of enzyme activity has been a focus of attention in recent years.[144,308–311] For example, Liu and co-workers designed a smart PA contrast agent (CPQ) for the sensing of cancer-related matrix metalloproteinases (MMPs).[144] CPQ has two specific absorption peaks at 930 and 680 nm, corresponding to absorbance of CuS and BHQ3, respectively. In the tumor microenvironment in which MMPs exist, MMP-sensitive peptides are cut and BHQ3 is released from CuS NPs. The former is rapidly removed from the tumor as a small molecule, while the latter\nAdv. Mater. 2019, 31, 1805875\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (17 of 31)\nremains in the tumor. Therefore, the PA intensity at 680 nm will be swiftly decreased, while that at 930 nm will remain intact (Figure 12A). In vivo detection of MMPs using PA imaging showed no obvious change in PA intensity at 680 nm during the first 2 h, while a dramatic decrease was observed at 6 and 24 h after the CPQ contrast agent was injected due to the time-lag in the MMP-induced cleavage of CPQ and the removal of released BHQ3 from the tumor. However, the PA intensity at both\nAdv. Mater. 2019, 31, 1805875\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (18 of 31)\n930 and 680 nm remained largely unchanged when employing MMP inhibitor-III, which inhibits MMP enzyme activity in vivo (Figure 12B). In addition, the PA signal ratio results were consistent with the imaging results (Figure 12C). The above phenomenon proves that the CPQ contrast agent can be employed to sense MMP enzyme activity by PA imaging. In another study, Gambhir and co-workers reported a furan-sensitive oligomerizable PA contrast agent, which was accumulated at the target site of enzyme activity during proteolysis and provided a responsive PA signal.[310] Thus, the PA imaging technique can be used to sense the activity of furfural and furan-like enzymes in cells and tumors. Recently, Lu and co-workers developed a DNA-aptamer-based PA-imaging contrast agent with a DNA chain and an NIR fluorophore/quencher pair with a contact-quenching effect.[311] Contact quenching was inhibited when binding of thrombin induced the release of DNA strands with the quenching agent, thus changing the PA signal ratio of 780 nm/725 nm (Figure 12D). For in vitro assay upon thrombin being injected into serum, the PA intensity at 725 nm was shown to gradually decline, while that at 780 nm only changed slightly with the increase in thrombin concentration; thus, the PA780nm/PA725nm ratio also increased (Figure 12E), suggesting that the PA contrast agent could be employed in complex body fluids. In an in vivo experiment in living mice, the PA intensities at 725 and 780 nm were remarkably enhanced after injection of the DNA-based contrast agent. Due to the dissociation of the DNA-aptamer-based PA contrast agent following activation by thrombin, the PA signal of thrombin-treated mice at 725 nm was much weaker than that of mice treated with phosphate buffered saline (PBS) at 45 min postinjection (Figure 12F,G); in addition, the PA780nm/PA725nm ratio of untreated and PBStreated mice was lower than that of thrombin-treated mice. The above results suggest that exogenous thrombin could activate the DNA-aptamer-based PA contrast agent in living mice, indicating its potential for advanced biomedical imaging in vivo."
    }, {
      "heading" : "5.6. Sensing of Temperature",
      "text" : "The delivery of contrast agents can be directly observed by PA imaging while visualizing the temperature distribution in vivo, thereby guiding and confirming the therapeutic effect of NP-mediated PTT.[312] Furthermore, the PA signal varies with change in temperature, yet techniques for the sensitive and quantitative measurement of temperature variation remain to be developed. For instance, Zheng and coworkers studied a stimuli-responsive PA contrast agent with J-aggregating NPs (JNPs) consisting of dipalmitoylphosphatidylcholine, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000],\nAdv. Mater. 2019, 31, 1805875\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (19 of 31)\nand Bchl-lipid (bacteriopheophorbide a-lipid), which were employed to sense the variation of temperature.[313] The color of the sample varied from dark brown to bright pink, with a decrease in absorption of the contrast agent at 824 nm and an increase at 750 nm with increasing temperature (Figure 13A). The repeated heating–cooling cycles gave rise to an analogous periodic variation of PA signals, suggesting that the temperature-sensing ability is reversible on heating–cooling cycles (Figure 13B). Based on the thermochromic characteristics of the above system, the contrast agent was successfully employed to noninvasively sense localized temperature variation in vivo and to monitor the thermal treatment of tumors (Figure 13C). Emelianov and co-workers designed NP-loaded poly(nisopropylacrylamide) (PNIPAM) nanogels to fabricate two stimuli-responsive PA contrast agents, namely PNIPAM-AuNR (Figure 13D) and PNIPAM-CuS respectively.[314] The diameter of PNIPAM is known to decrease rapidly with the temperature surpassing its critical temperature (32 °C) and to expand and recover its initial diameter with a subsequent decrease in temperature. This occurs due to the reversible phase transition of the hydrophobic structure of PNIPAM chain (Figure 13E). The PA signal of PNIPAM-CuS increased significantly with the rise in temperature, and PA signal of PNIPAM-CuS was higher than that of pure CuS (Figure 13F). Furthermore, the CuS instantly heated the PNIPAM cage when a continuous-wave (CW) laser was switched on, resulting in a significant increase in the PA signal in the PNIPAM-CuS region, with a periodic repeated increasing pattern upon laser irradiation or lack thereof (Figure 13G). The PA signal was correspondingly observed to increase over the first 30 s of laser irradiation (Figure 13H), while PA signal decreased over the following 30 s during which the laser radiation was turned off. In a subsequent experiment,\nAdv. Mater. 2019, 31, 1805875\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (20 of 31)\nthe contrast agent poly(n-isopropylacrylamide-acrylamide)AuNR (PNIPAM-AM-AuNR), which has a higher critical temperature than the normal physiological temperature of mice, was employed to perform in vivo imaging. The vast majority of PNIPAM-AM-AuNR was removed from the blood vessels (Figure 13I) and accumulated in the tumor at 24 h postinjection. Comparing the PA images of the CW laser off and on, an enhancement of the PA signal was recorded only in the tumor region where PNIPAM-AM-AuNR was accumulated (Figure 13J,K). Furthermore, the PNIPAM-AM-AuNR contrast\nAdv. Mater. 2019, 31, 1805875\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (21 of 31)\nagent showed an over fivefold PA contrast enhancement in vivo when employing dynamic-contrast-enhanced PA imaging (Figure 13L).[314] Dynamic-contrast-enhanced PA imaging is a new imaging processing approach able to suppress background signals to further improve PA contrast."
    }, {
      "heading" : "5.7. Sensing of Hypoxia",
      "text" : "A lack of oxygen supply leads to hypoxia, which damages physiological function and is the pathological feature of many diseases, including cancer and ischemia.[315–318] Therefore, sensing of hypoxia could guide the therapeutic regimen and could be used as a predictor of patient prognosis.[319–322] Chan and co-workers developed a hypoxia-responsive PA-imaging contrast agent with a N-oxide trigger (HyP-1), which can be reduced in conditions without oxygen, while the reduction of Hyp-1 (absorption at 670 nm) produces a different spectral product (Red-Hyp-1; absorption at 760 nm) easily identified by PA imaging (Figure 14A).[319] HyP-1 has a high selectivity for hypoxic activation in vivo. For in vitro tests, the PA intensity under hypoxic condition was shown to be fourfold higher\nAdv. Mater. 2019, 31, 1805875\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (22 of 31)\nAdv. Mater. 2019, 31, 1805875\nthan that under normoxic conditions when irradiated using a 770 nm laser (Figure 14B). For in vivo tests, the PA signal of the hypoxic tumor region increased gradually and reached maximum at 3 h when the Red-Hyp-1 is highly accumulated; conversely, no obvious increase was observed in the control group (Figure 14C,D). In addition, the PA signal from the ischemic increased by 3.1 times over that of the control group (Figure 14E), suggesting that the HyP-1 contrast agent can be employed in hypoxia sensing in multiple disease models. On this basis, Knox et al. developed a hypoxia-responsive contrast agent, rHyP-1, with a high and low PA signal ratio for hypoxia and normoxia, respectively (Figure 14F).[320] In vitro PA imaging experiments of rHyP-1 showed the PA820nm/PA770nm ratio of the hypoxic condition to be 2-fold that under normoxic condition (Figure 14G). Significantly, the rHyP-1 PA contrast agent not only can sense hypoxia within the intratumor, but also can estimate the area of contrast agent activation in tumors. Furthermore, in an in vivo tumor model, the largest hypoxic region and location of rHyP-1 activation was determined through 3D reconstruction ratiometric PA imaging (Figure 14H,I). In addition, the sensing of H2S[323,324] and protein interactions in vivo[325] could also be performed through PA imaging."
    }, {
      "heading" : "5.8. Imaging of LNs",
      "text" : "Metastases, rather than the primary tumor, the cause of most cancer patients, with cancer cells often damaging local LNs before metastasizing to other organs.[326] Therefore, imaging of LNs is an essential technique to study tumor staging and prognosis. To date, PA-imaging technology has been widely employed in real-time LN mapping.[89,126,327–331] In 2013, Emelianov and co-workers[89] developed silica-coated Au nanoplates (SPNs) as a PA contrast agent for sentinel LN (SLN) imaging. The SPNs exhibited a strong, persistent PA signal that could be rapidly transferred to the SLN and gradually spread throughout most nodes. Later, Pu et al. used a stable contrast agent, SPN1, to map the LNs in mice.[238] Briefly, after SPN1 was injected intravenously into healthy mice for 24 h, an amplified PA signal was observed in the brachial, inguinal, and superficial cervical LNs. In the another study, Liu and o-workers designed a type of conjugated-oligomer-based NPs (N4) as a PA-imaging contrast agent for the real-time imaging of the SLN.[330] In vivo experiments by injecting an N4 contrast agent into the left forepaw pad of mouse showed a negligible PA contrast in the SLN prior to injection (Figure 15A), with a maximum signal at 10 min postinjection (Figure 15B), followed by a gradual decline at 20 min postinjection (Figure 15C) and still detectable at 90 min postinjection (Figure 15D). The 3D PA SLN imaging corresponding to the different time points (Figure 15E,F) showed the same results. These results suggested that the N4 contrast agent possessed the merits of excellent biocompatibility, photostability, and rapid body clearance, therefore, inhibiting cancer metastasis at SLNs through PA-imaging-guided PTT. Recently, Emelianov and co-workers combined CuS NPs and laser-activated perfluorocarbon nanodroplets as a contrast agent in the NIR absorption window at 1064 nm for hyperpermeable LN vasculature imaging by both PA and US.[142] The CuS NPs were used as a photoabsorber\nto initiate the vaporization of perfluorocarbon nanodroplets, leading to phase-change and a subsequent enhanced PA signal, generating a gaseous perfluorocarbon microbubble to increase the US contrast signal (Figure 15G). In another example, Chen and co-workers studied the size-dependent PA imaging of lymphatic system after local administration of PDI NPs, concluding that NPs of 100 nm in size led to the best distinction in sciatic LNs from popliteal LNs (Figure 15H),[210] because it takes ≈1 h for the NPs of 100 nm in size to migrate from popliteal LNs to sciatic LNs; the 1 h interval is long enough for surgeons to make pathological analysis and to determine the following surgery."
    }, {
      "heading" : "5.9. Imaging of Vasculature In Vitro and In Vivo",
      "text" : "PA imaging has also been employed to evaluate the treatment efficacy of vasculature-related diseases such as atherosclerosis and thrombus.[207,332–341] For example, Fan and co-workers prepared cRGD-PDI NPs that bind glycoprotein IIb/IIIa (GPIIb/IIIa), which can specifically highlight early thrombus by PA imaging. The PA signal was shown to be enhanced in early thrombus, which expresses a high level of GPIIb/IIIa, but not in older thrombus, with a low level of GPIIb/IIIa (Figure 16A–C). In addition, the effects of thrombolysis could be monitored in real time using cRGD-PDI NPs. PA imaging showed an irregular margin in the vessel surrounding the highlighted thrombus; however, when the thrombolytic agent was injected, the margin was gradually smoothed out and eventually regained the appearance of a normal vessel (Figure 16C). Lee and co-workers reported a PA contrast agent and theranostic nanoagent (T-FBM) offering an enhanced PA signal via H2O2triggered CO2-bubble production that is suitable in the treatment of H2O2-associated vascular diseases through the release of anti-inflammatory agents and antioxidants (Figure 16D).[339] In an in vivo mouse model of FeCl3-induced arterial thrombosis (Figure 16E), T-FBM NPs showed a stronger ratiometric (thrombus/normal tissue) PA signal than that of the control nanoagent T-FPLGA (Figure 16F,H), proving the good targeting ability of T-FBM NPs to thrombus. More importantly, T-FBM NPs reacted with endogenous H2O2, increasing the PA signals of thrombus, without the end of external laser radiation."
    }, {
      "heading" : "5.10. Brain Imaging",
      "text" : "PA imaging has also been widely used in brain imaging.[129,206,342–349] For example, Sailor and co-workers developed an effective PA contrast agent, Ca-pSiNP-ICG, in which ICG was encapsulated in porous silicon NPs via a calcium silicate precipitation method for ex vivo mouse-brain imaging.[221] Compared with the free ICG or PBS controls, which had weak and nonexistent PA signals, respectively, the Ca-pSiNPICG injected into the brain showed an enhanced PA signal (Figure 17A). In another study, Nie and co-workers employed modified Prussian blue NP-labeled bone mesenchymal stem cells to monitor traumatic brain injury (TBI) and its rehabilitation by PA imaging (Figure 17B).[350] Following craniocerebral injury in mice, the process of natural recovery in the TBI region\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (23 of 31)\nAdv. Mater. 2019, 31, 1805875\ntakes half a month (Figure 17C,D); interestingly, rehabilitation time with intravenously injected bone mesenchymal stem cells in mice was reduced to ≈5 d (Figure 17E). Furthermore, the removal rate of blood clots without the stem cell injection was ≈15 d, which was reduced to 160 h to return to normal tissue levels following stem cell injection (Figure 17F). The above pheno menon proved that PA imaging can be employed not only observe brain damage and recovery but also to trace stem cells within the pathological region. In recent years, more examples have demonstrated the feasibility for brain PA imaging.[351–354]"
    }, {
      "heading" : "6. Conclusions and Outlook",
      "text" : "PA-imaging technology has the advantages of safety, high resolution, and real-time imaging, and can offer vital information on biological tissue structure, function, meta bolism, and genetic variation. Furthermore, it has been shown to have important\napplications in various biomedical fields, including: (1) in-depth study of cardiovascular disease, (2) drug monitoring, (3) tumor imaging, (4) gene expression, (5) stem cells and immune system, and (6) sensing and early diagnosis of disease.\nPA contrast agents are signal contrast intensifiers and significantly improve the PA-imaging ability and quality, including resolution and contrast, through the alteration of the PA characteristics of local tissue. Over the last few years, a variety of contrast agents have been explored for PA imaging. Here, we have summarized and reviewed the various types of contrast agents, including both inorganic and organic contrast agents, as well as their applications in biomedicine. The use of PA imaging and specific contrast agents in the biosensing of metal ions, pH, ROS, RNS, enzymes, temperature, and hypoxia, as well as in the bioimaging of tumor, LNs, vasculature, and brain function are also elaborated. Through the further development of biomedicine and interventional therapies, the application of PA contrast agents will become ever more extensive. To date, the study of PA contrast agents focuses on two main aspects; first,\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (24 of 31)\nAdv. Mater. 2019, 31, 1805875\nthe modification of existing PA imaging materials by chemical modification or their combination with other functionalized materials to form new multifunctional systems, and second, on the development of new and efficient PA contrast agents to overcome the shortcomings of traditional contrast agents whilst simultaneously achieving more efficient PA imaging.\nAlthough there have been various reports focusing on PA contrast agents in recent years, the study of contrast agents remains at the laboratory stage. Although different types of contrast agent possess respective merits, most nanomaterials used in PA imaging exhibit various issues, such as relatively poor biocompatibility, the requirement of large doses of nanoagents, poor targeting effect, suboptimal tissue biodistribution, lack of proper evaluation of pharmacokinetics, and difficulty to be accurately quantified, among others (Table 2). Therefore, there remains a long path in the study of PA contrast agents. Future\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (26 of 31)\nAdv. Mater. 2019, 31, 1805875\nwork should focus on the development of highly efficient, stable, low-cost, functionalized, and novel contrast agents, considering the following two aspects: (1) optimization of optical properties, including molar absorption coefficient and NIR absorption wavelength, and (2) optimization of biological characteristics, including immunogenicity, toxicity, and particle size. Thus, the design and synthesis of biomaterials with excellent optical and biological properties will become a focus of attention in the field of bioimaging. Through extensive and systematic research in biomaterials, the structure and properties of nanomaterials are now more deeply understood. With this knowledge and the help of high-quality imaging techniques, the PA-imaging technology and PA contrast agents will be rapidly developed and widely applied."
    }, {
      "heading" : "Acknowledgements",
      "text" : "This work was supported by the National Natural Science Foundation of China (Nos. U1505221, 21635002, 21874024, and 21475026), the Program for Changjiang Scholars and Innovative Research Team in University (No. IRT15R11), the Health-Education joint research project of Fujian Province (No. KJ2016-2-23), Minjiang Scholars of Fujian Province, and the Intramural Research Program (IRP) of the NIBIB, NIH.\nConflict of Interest The authors declare no conflict of interest.\nKeywords bioimaging, biomedical application, biosensing, contrast agents, photoacoustic imaging\nReceived: September 10, 2018 Revised: October 10, 2018\nPublished online: December 17, 2018\n[1] X. Wang, Y. Pang, G. Ku, X. Xie, G. Stoica, L. V. Wang, Nat. Biotechnol. 2003, 21, 803. [2] L. V. Wang, S. Hu, Science 2012, 335, 1458. [3] P. Beard, Interface Focus 2011, 1, 602. [4] K. Wilson, K. Homan, S. Emelianov, Nat. Commun. 2012, 3, 618. [5] S. Zackrisson, S. M. W. Y. van de Ven, S. S. Gambhir, Cancer Res.\n2014, 74, 979. [6] S. Manohar, A. Van Apeldoorn, W. Steenbergen, Nat. Photonics\n2015, 9, 216. [7] F. A. McDonald, G. C. Wetsel, J. Appl. Phys. 1978, 49, 2313. [8] A. G. Bell, Am. J. Sci 1880, 20, 305. [9] L. V. Wang, Med. Phys. 2008, 35, 5758.\n[10] S. Wang, J. Lin, T. Wang, X. Chen, P. Huang, Theranostics 2016, 6, 2394. [11] L. V. Wang, Nat. Photonics 2009, 3, 503. [12] M. Xu, L. V. Wang, Rev. Sci. Instrum. 2006, 77, 041101. [13] H. F. Zhang, K. Maslov, G. Stoica, L. V. Wang, Nat. Biotechnol.\n2006, 24, 848. [14] C. Kim, C. Favazza, L. V. Wang, Chem. Rev. 2010, 110, 2756. [15] L. V. Wang, J. Yao, Nat. Methods 2016, 13, 627.\n[16] D. Pan, B. Kim, L. V. Wang, G. M. Lanza, Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. 2013, 5, 517. [17] J. Weber, P. C. Beard, S. E. Bohndiek, Nat. Methods 2016, 13, 639. [18] C. J. Reinhardt, J. Chan, Biochemistry 2018, 57, 194. [19] L. Zeng, G. Ma, J. Lin, P. Huang, Small 2018, e1800782. [20] D. Wu, L. Huang, M. S. Jiang, H. Jiang, Int. J. Mol. Sci. 2014, 15,\n23616. [21] J. Xia, L. V. Wang, IEEE Trans. Bio-Med. Eng. 2014, 61, 1380. [22] Y. Jin, C. Jia, S. W. Huang, M. O’donnell, X. Gao, Nat. Commun.\n2010, 1, 41. [23] L. Nie, X. Chen, Chem. Soc. Rev. 2014, 43, 7132. [24] Q. Fan, K. Cheng, X. Hu, X. Ma, R. Zhang, M. Yang, X. Lu, L. Xing,\nW. Huang, S. S. Gambhir, Z. Cheng, J. Am. Chem. Soc. 2014, 136, 15185. [25] S. Hu, K. Maslov, L. V. Wang, Opt. Lett. 2011, 36, 1134. [26] G. S. Sangha, E. H. Phillips, C. J. Goergen, Biomed. Opt. Express\n2017, 8, 736. [27] P. Wang, P. Wang, H.-W. Wang, J.-X. Cheng, J. Biomed. Opt. 2012,\n17, 096010. [28] W. Li, X. Chen, Nanomedicine 2015, 10, 299. [29] Z. Liu, S. Tabakman, K. Welsher, H. Dai, Nano Res. 2009, 2, 85. [30] H. Gong, R. Peng, Z. Liu, Adv. Drug Delivery Rev. 2013, 65, 1951. [31] J. Lin, X. Chen, P. Huang, Adv. Drug Delivery Rev. 2016, 105, 242. [32] Y. Chen, C. Tan, H. Zhang, L. Wang, Chem. Soc. Rev. 2015, 44,\n2681. [33] J. Kim, S. Park, C. Lee, J. Y. Kim, C. Kim, ChemNanoMat 2016, 2,\n156. [34] Y. Jiang, K. Pu, Small 2017, 13, 1700710. [35] K. Pu, N. Chattopadhyay, J. Rao, J. Controlled Release 2016, 240,\n312. [36] L. Cui, J. Rao, Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.\n2017, 9, e1418. [37] D. Cui, C. Xie, K. Pu, Macromol. Rapid. Commun. 2017, 38,\n1700125. [38] Y. Lyu, K. Pu, Adv. Sci. 2017, 4, 1600481. [39] J. Li, J. Rao, K. Pu, Biomaterials 2018, 155, 217. [40] L. Zhou, H. Zhou, C. Wu, Wiley Interdiscip. Rev.: Nanomed. Nano-\nbiotechnol. 2018, 10, 1510. [41] Y. Liu, L. Nie, X. Chen, Trends Biotechnol. 2016, 34, 420. [42] S. Mallidi, G. P. Luke, S. Emelianov, Trends Biotechnol. 2011, 29,\n213. [43] K. S. Valluru, J. K. Willmann, Ultrasonography 2016, 35, 267. [44] X. Huang, J. Song, B. C. Yung, X. Huang, Y. Xiong, X. Chen, Chem.\nSoc. Rev. 2018, 47, 2873. [45] A. Taruttis, V. Ntziachristos, Nat. Photonics 2015, 9, 219. [46] Y. Zhai, W. Ran, J. Su, T. Lang, J. Meng, G. Wang, P. Zhang, Y. Li,\nAdv. Mater. 2018, 30, 1802378. [47] D. Zhang, Z. Wang, L. Wang, H. Wang, G. Li, Z. Y. Qiao, W. Xu,\nACS Appl. Mater. Interfaces 2018, 10, 28331. [48] R. Guo, Y. Tian, Y. Yang, Q. Jiang, Y. Wang, W. Yang, Adv. Funct.\nMater. 2018, 28, 1706398. [49] Y.-S. Chen, W. Frey, S. Kim, P. Kruizinga, K. Homan, S. Emelianov,\nNano Lett. 2011, 11, 348. [50] P. Huang, J. Lin, W. Li, P. Rong, Z. Wang, S. Wang, X. Wang,\nX. Sun, M. Aronova, G. Niu, R. D. Leapman, Z. Nie, X. Chen, Angew. Chem., Int. Ed. 2013, 52, 13958. [51] M. Chen, S. Tang, Z. Guo, X. Wang, S. Mo, X. Huang, G. Liu, N. Zheng, Adv. Mater. 2014, 26, 8210. [52] H. Moon, D. Kumar, H. Kim, C. Sim, J.-H. Chang, J.-M. Kim, H. Kim, D.-K. Lim, ACS Nano 2015, 9, 2711. [53] C. Kim, E. C. Cho, J. Chen, K. H. Song, L. Au, C. Favazza, Q. Zhang, C. M. Cobley, F. Gao, Y. Xia, L. V. Wang, ACS Nano 2010, 4, 4559. [54] X. Cheng, R. Sun, L. Yin, Z. Chai, H. Shi, M. Gao, Adv. Mater. 2017, 29, 1604894.\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (27 of 31)\nAdv. Mater. 2019, 31, 1805875\n[55] Y. Zhang, G. Wang, L. Yang, F. Wang, A. Liu, Coord. Chem. Rev. 2018, 370, 1. [56] Y. Yan, L. Liu, Z. Cai, J. Xu, Z. Xu, D. Zhang, X. Hu, Sci. Rep. 2016, 6, 31328. [57] H. Nishi, T. Asahi, S. Kobatake, J. Phys. Chem. C 2011, 115, 4564. [58] E. Petryayeva, U. J. Krull, Anal. Chim. Acta 2011, 706, 8. [59] J. Cao, T. Sun, K. T. V. Grattan, Sens. Actuators, B 2014, 195, 332. [60] J. V. Jokerst, A. J. Cole, D. V. Sompel, S. S. Gambhir, ACS Nano\n2012, 6, 10366. [61] A. Agarwal, S. W. Huang, M. O’Donnell, K. C. Day, M. Day,\nN. Kotov, S. Ashkenazi, J. Appl. Phys. 2007, 102, 064710. [62] P.-J. Chen, S.-H. Hu, C.-T. Fan, M.-L. Li, Y.-Y. Chen, S.-Y. Chen,\nD.-M. Liu, Chem. Commun. 2013, 49, 892. [63] J. Song, X. Yang, O. Jacobson, P. Huang, X. Sun, L. Lin, X. Yan,\nG. Niu, Q. Ma, X. Chen, Adv. Mater. 2015, 27, 4910. [64] J. Zhong, L. Wen, S. Yang, L. Xiang, Q. Chen, D. Xing, Nanomed.\nNanotechnol. 2015, 11, 1499. [65] L. Tong, Q. Wei, A. Wei, J. X. Cheng, Photochem. Photobiol. 2009,\n85, 21. [66] N. Yan, X. Wang, L. Lin, T. Song, P. Sun, H. Tian, H. Liang,\nX. Chen, Adv. Funct. Mater. 2018, 28, 1800490. [67] C. Bao, J. Conde, F. Pan, C. Li, C. Zhang, F. Tian, S. Liang,\nJ. M. de la Fuente, D. Cui, Nano Res. 2016, 9, 1043. [68] M. Perez-Hernandez, P. del Pino, S. G. Mitchell, M. Moros,\nG. Stepien, B. Pelaz, W. J. Parak, E. M. Galvez, J. Pardo, J. M. de la Fuente, ACS Nano 2015, 9, 52. [69] R. Liang, J. Xie, J. Li, K. Wang, L. Liu, Y. Gao, M. Hussain, G. Shen, J. Zhu, J. Tao, Biomaterials 2017, 149, 41. [70] S. E. Skrabalak, J. Chen, Y. Sun, X. Lu, L. Au, C. M. Cobley, Y. Xia, Acc. Chem. Res. 2008, 41, 1587. [71] K. H. Song, C. Kim, C. M. Cobley, Y. Xia, L. V. Wang, Nano Lett. 2009, 9, 183. [72] G. D. Moon, S.-W. Choi, X. Cai, W. Li, E. C. Cho, U. Jeong, L. V. Wang, Y. Xia, J. Am. Chem. Soc. 2011, 133, 4762. [73] Y. Xia, W. Li, C. M. Cobley, J. Chen, X. Xia, Q. Zhang, M. Yang, E. C. Cho, P. K. Brown, Acc. Chem. Res. 2011, 44, 914. [74] X. Yang, S. E. Skrabalak, Z.-Y. Li, Y. Xia, L. V. Wang, Nano Lett. 2007, 7, 3798. [75] C.-W. Wei, M. Lombardo, K. Larson-Smith, I. Pelivanov, C. Perez, J. Xia, T. Matula, D. Pozzo, M. O’Donnell, Appl. Phys. Lett. 2014, 104, 033701. [76] A. Prost, F. Poisson, E. Bossy, Phys. Rev. B 2015, 92, 115450. [77] W. Lu, Q. Huang, G. Ku, X. Wen, M. Zhou, D. Guzatov, P. Brecht,\nR. Su, A. Oraevsky, L. V. Wang, C. Li, Biomaterials 2010, 31, 2617. [78] W. Lu, M. P. Melancon, C. Xiong, Q. Huang, A. Elliott, S. Song,\nR. Zhang, L. G. Flores II, J. G. Gelovani, L. V. Wang, G. Ku, R. J. Stafford, C. Li, Cancer Res. 2011, 71, 6116. [79] W. Wang, C. Hao, M. Sun, L. Xu, C. Xu, H. Kuang, Adv. Funct. Mater. 2018, 28, 1800310. [80] W. Li, X. Sun, Y. Wang, G. Niu, X. Chen, Z. Qian, L. Nie, Biomed. Opt. Express 2014, 5, 2679. [81] J. An, X.-Q. Yang, K. Cheng, X.-L. Song, L. Zhang, C. Li, X.-S. Zhang, Y. Xuan, Y.-Y. Song, B.-Y. Fang, X.-L. Hou, Y.-D. Zhao, B. Liu, ACS Appl. Mater. Interfaces 2017, 9, 41748. [82] X. Li, L. Xing, K. Zheng, P. Wei, L. Du, M. Shen, X. Shi, ACS Appl. Mater. Interfaces 2017, 9, 5817. [83] V. Raghavan, C. O’Flatharta, R. Dwyer, A. Breathnach, H. Zafar, P. Dockery, A. Wheatley, I. Keogh, M. Leahy, M. Olivo, Nanomedicine 2017, 12, 457. [84] J. S. Wi, J. Park, H. Kang, D. Jung, S. W. Lee, T. G. Lee, ACS Nano 2017, 11, 6225. [85] Q. Yu, P. Guan, D. Qin, G. Golden, P. M. Wallace, Nano Lett. 2008, 8, 1923. [86] I. Zoric, M. Zach, B. Kasemo, C. Langhammer, ACS Nano 2011, 5, 2535.\n[87] M. L. Personick, M. R. Langille, J. Zhang, N. Harris, G. C. Schatz, C. A. Mirkin, J. Am. Chem. Soc. 2011, 133, 6170. [88] M. Morsin, M. M. Salleh, A. A. Umar, M. Z. Sandan, Sensors 2017, 17, 947. [89] G. P. Luke, A. Bashyam, K. A. Homan, S. Makhija, Y.-S. Chen, S. Y. Emelianov, Nanotechnology 2013, 24, 455101. [90] J. Song, X. Yang, Z. Yang, L. Lin, Y. Liu, Z. Zhou, Z. Shen, G. Yu, Y. Dai, O. Jacobson, J. Munasinghe, B. Yung, G. J. Teng, X. Chen, ACS Nano 2017, 11, 6102. [91] H. Ke, J. Wang, S. Tong, Y. Jin, S. Wang, E. Qu, G. Bao, Z. Dai, Theranostics 2014, 4, 12. [92] J. Zhao, M. Wallace, M. P. Melancon, Nanomedicine 2014, 9, 2041. [93] V. Weber, A. Feis, C. Gellini, R. Pilot, P. R. Salvi, R. Signorini, Phys. Chem. Chem. Phys. 2015, 17, 21190. [94] K. Cheng, S.-R. Kothapalli, H. Liu, A. L. Koh, J. V. Jokerst, H. Jiang, M. Yang, J. Li, J. Levi, J. C. Wu, S. S. Gambhir, Z. Cheng, J. Am. Chem. Soc. 2014, 136, 3560. [95] Y. Liu, Z. Yang, X. Huang, G. Yu, S. Wang, Z. Zhou, Z. Shen, W. Fan, M. Davisson, H. Kalish, G. Niu, Z. Nie, X. Chen, ACS Nano 2018, 12, 8129. [96] P. K. Jain, K. S. Lee, I. H. El-Sayed, M. A. El-Sayed, J. Phys. Chem. B 2006, 110, 7238. [97] B. Nikoobakht, M. A. El-Sayed, Chem. Mater. 2003, 15, 1957. [98] J. V. Jokerst, M. Thangaraj, P. J. Kempen, R. Sinclair, S. S. Gambhir,\nACS Nano 2012, 6, 5920. [99] T. Kim, Q. Zhang, J. Li, L. Zhang, J. V. Jokerst, ACS Nano 2018, 12,\n5615. [100] C. Bao, N. Beziere, P. del Pino, B. Pelaz, G. Estrada, F. Tian,\nV. Ntziachristos, J. M. de la Fuente, D. Cui, Small 2013, 9, 68. [101] S. Raveendran, H. T. Lim, T. Maekawa, M. Vadakke Matham,\nD. S. Kumar, Nanoscale 2018, 10, 13959. [102] H. Yuan, C. G. Khoury, H. Hwang, C. M. Wilson, G. A. Grant,\nT. Vo-Dinh, Nanotechnology 2012, 23, 075102. [103] T. C. Preston, R. Signorell, ACS Nano 2009, 3, 3696. [104] S. Mallidi, T. Larson, J. Tam, P. P. Joshi, A. Karpiouk, K. Sokolov,\nS. Emelianov, Nano Lett. 2009, 9, 2825. [105] D. Liu, F. Zhou, C. Li, T. Zhang, H. Zhang, W. Cai, Y. Li, Angew.\nChem., Int. Ed. 2015, 54, 9596. [106] J. Song, L. Pu, J. Zhou, B. Duan, H. Duan, ACS Nano 2013, 7,\n9947. [107] L. Y. Bai, X. Q. Yang, J. An, L. Zhang, K. Zhao, M. Y. Qin, B. Y. Fang,\nC. Li, Y. Xuan, X. S. Zhang, Y. D. Zhao, Z. Y. Ma, Nanotechnology 2015, 26, 315701. [108] J. M. Tam, J. O. Tam, A. Murthy, D. R. Ingram, L. L. Ma, K. Travis, K. P. Johnston, K. V. Sokolov, ACS Nano 2010, 4, 2178. [109] J. Song, G. Niu, X. Chen, Bioconjugate Chem. 2017, 28, 105. [110] J. Song, L. Cheng, A. Liu, J. Yin, M. Kuang, H. Duan, J. Am. Chem.\nSoc. 2011, 133, 10760. [111] J. Song, J. Zhou, H. Duan, J. Am. Chem. Soc. 2012, 134, 13458. [112] J. Song, P. Huang, H. Duan, X. Chen, Acc. Chem. Res. 2015, 48,\n2506. [113] P. Huang, J. Lin, W. Li, P. Rong, Z. Wang, S. Wang, X. Wang,\nX. Sun, M. Aronova, G. Niu, R. D. Leapman, Z. Nie, X. Chen, Angew. Chem., Int. Ed. 2013, 125, 14208. [114] Y. S. Chen, Y. C. Hung, I. Liau, G. S. Huang, Nanoscale Res. Lett. 2009, 4, 858. [115] H. Deng, F. Dai, G. Ma, X. Zhang, Adv. Mater. 2015, 27, 3645. [116] C. Loo, A. Lowery, N. Halas, J. West, R. Drezek, Nano Lett. 2005,\n5, 709. [117] Y. Liu, J. He, K. Yang, C. Yi, L. Nie, N. M. Khashab, X. Chen, Z. Nie,\nAngew. Chem., Int. Ed. 2015, 54, 15809. [118] J. Song, B. Wu, Z. Zhou, G. Zhu, Y. Liu, Z. Yang, L. Lin, G. Yu,\nF. Zhang, G. Zhang, H. Duan, G. D. Stucky, X. Chen, Angew. Chem., Int. Ed. 2017, 56, 8110.\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (28 of 31)\nAdv. Mater. 2019, 31, 1805875\n[119] K. Homan, J. Shah, S. Gomez, H. Gensler, A. Karpiouk, L. Brannon-Peppas, S. Emelianov, J. Biomed. Opt. 2010, 15, 021316. [120] X. Wang, L. Zhang, J. Wang, X. Liu, P. Lv, J. Zeng, G. Liu, J. Biomed. Nanotechnol. 2018, 14, 1448. [121] K. A. Homan, M. Souza, R. Truby, G. P. Luke, C. Green, E. Vreeland, S. Emelianov, ACS Nano 2012, 6, 641. [122] L. Nie, M. Chen, X. Sun, P. Rong, N. Zheng, X. Chen, Nanoscale 2014, 6, 1271. [123] M. Chen, S. Chen, C. He, S. Mo, X. Wang, G. Liu, N. Zheng, Nano Res. 2017, 10, 1234. [124] X. Chen, S. Shi, J. Wei, M. Chen, N. Zheng, Sci. Bull. 2017, 62, 579. [125] M. Chen, Z. Guo, Q. Chen, J. Wei, J. Li, C. Shi, D. Xu, D. Zhou,\nX. Zhang, N. Zheng, Chem. Sci. 2018, 9, 4268. [126] D. Pan, X. Cai, C. Yalaz, A. Senpan, K. Omanakuttan,\nS. A. Wickline, L. V. Wang, G. M. Lanza, ACS Nano 2012, 6, 1260. [127] X.-R. Song, X. Wang, S.-X. Yu, J. Cao, S.-H. Li, J. Li, G. Liu,\nH.-H. Yang, X. Chen, Adv. Mater. 2015, 27, 3285. [128] L. Chen, X. Zhou, W. Nie, W. Feng, Q. Zhang, W. Wang, Y. Zhang,\nZ. Chen, P. Huang, C. He, ACS Appl. Mater. Interfaces 2017, 9, 17786. [129] C. Liu, J. Chen, Y. Zhu, X. Gong, R. Zheng, N. Chen, D. Chen, H. Yan, P. Zhang, H. Zheng, Z. Sheng, L. Song, Nano-Micro Lett. 2018, 10, 1. [130] J. Yu, W. Yin, X. Zheng, G. Tian, X. Zhang, T. Bao, X. Dong, Z. Wang, Z. Gu, X. Ma, Y. Zhao, Theranostics 2015, 5, 931. [131] J. Chen, C. Liu, D. Hu, F. Wang, H. Wu, X. Gong, X. Liu, L. Song, Z. Sheng, H. Zheng, Adv. Funct. Mater. 2016, 26, 8715. [132] W. Yang, W. Guo, W. Le, G. Lv, F. Zhang, L. Shi, X. Wang, J. Wang, S. Wang, J. Chang, B. Zhang, ACS Nano 2016, 10, 10245. [133] G. Chen, B. Ma, Y. Wang, R. Xie, C. Li, K. Dou, S. Gong, ACS Appl. Mater. Interfaces 2017, 9, 41700. [134] L. Zhang, S. Gao, F. Zhang, K. Yang, Q. Ma, L. Zhu, ACS Nano 2014, 8, 12250. [135] C. Lu, G. Chen, B. Yu, H. Cong, Adv. Eng. Mater. 2018, 20, 1700940. [136] K. Zhang, Z. Yang, X. Meng, Y. Cao, Y. Zhang, W. Dai, H. Lu, Z. Yu, H. Dong, X. Zhang, Mater. Chem. Front. 2018, 2, 1184. [137] K. Huang, Z. Li, J. Lin, G. Han, P. Huang, Chem. Soc. Rev. 2018, 47, 5109. [138] L. Cheng, J. Liu, X. Gu, H. Gong, X. Shi, T. Liu, C. Wang, X. Wang, G. Liu, H. Xing, W. Bu, B. Sun, Z. Liu, Adv. Mater. 2014, 26, 1886. [139] X. Qian, S. Shen, T. Liu, L. Cheng, Z. Liu, Nanoscale 2015, 7, 6380. [140] R. Y. Zhang, Z. Y. Wang, X. Q. Yang, Y. Xuan, K. Cheng, C. Li,\nX. L. Song, J. An, X. L. Hou, Y. D. Zhao, Nanotechnology 2018, 29, 055101. [141] G. Ku, M. Zhou, S. Song, Q. Huang, J. Hazle, C. Li, ACS Nano 2012, 6, 7489. [142] D. Y. Santiesteban, D. S. Dumani, D. Profili, S. Y. Emelianov, Nano Lett. 2017, 17, 5984. [143] W. Gao, Y. Sun, M. Cai, Y. Zhao, W. Cao, Z. Liu, G. Cui, B. Tang, Nat. Commun. 2018, 9, 231. [144] K. Yang, L. Zhu, L. Nie, X. Sun, L. Cheng, C. Wu, G. Niu, X. Chen, Z. Liu, Theranostics 2014, 4, 134. [145] G. Lv, W. Guo, W. Zhang, T. Zhang, S. Li, S. Chen, A. S. Eltahan, D. Wang, Y. Wang, J. Zhang, P. C. Wang, J. Chang, X. J. Liang, ACS Nano 2016, 10, 9637. [146] Z. Li, H. Zhang, J. Han, Y. Chen, H. Lin, T. Yang, Adv. Mater. 2018, 30, 1706981. [147] H. Lin, S. Gao, C. Dai, Y. Chen, J. Shi, J. Am. Chem. Soc. 2017, 139, 16235. [148] A. De La Zerda, C. Zavaleta, S. Keren, S. Vaithilingam, S. Bodapati, Z. Liu, J. Levi, B. R. Smith, T.-J. Ma, O. Oralkan, Z. Cheng, X. Chen, H. Dai, B. T. Khuri-Yakub, S. S. Gambhir, Nat. Nanotechnol. 2008, 3, 557.\n[149] J.-W. Kim, E. I. Galanzha, E. V. Shashkov, H.-M. Moon, V. P. Zharov, Nat. Nanotechnol. 2009, 4, 688. [150] L. Meng, X. Zhang, Q. Lu, Z. Fei, P. J. Dyson, Biomaterials 2012, 33, 1689. [151] J. Liu, C. Wang, X. Wang, X. Wang, L. Cheng, Y. Li, Z. Liu, Adv. Funct. Mater. 2015, 25, 384. [152] K. Yang, L. Hu, X. Ma, S. Ye, L. Cheng, X. Shi, C. Li, Y. Li, Z. Liu, Adv. Mater. 2012, 24, 1868. [153] G. Lalwani, X. Cai, L. Nie, L. V. Wang, B. Sitharaman, Photoacoustics 2013, 1, 62. [154] M. A. Patel, H. Yang, P. L. Chiu, D. D. T. Mastrogiovanni, C. R. Flach, K. Savaram, L. Gomez, A. Hemnarine, R. Mendelsohn, E. Garfunkel, H. Jiang, H. He, ACS Nano 2013, 7, 8147. [155] Y.-W. Wang, Y.-Y. Fu, Q. Peng, S.-S. Guo, G. Liu, J. Li, H.-H. Yang, G.-N. Chen, J. Mater. Chem. B 2013, 1, 5762. [156] D. Hu, J. Zhang, G. Gao, Z. Sheng, H. Cui, L. Cai, Theranostics 2016, 6, 1043. [157] Y. Toumia, F. Domenici, S. Orlanducci, F. Mura, D. Grishenkov, P. Trochet, S. Lacerenza, F. Bordi, G. Paradossi, ACS Appl. Mater. Interfaces 2016, 8, 16465. [158] Z. Sheng, L. Song, J. Zheng, D. Hu, M. He, M. Zheng, G. Gao, P. Gong, P. Zhang, Y. Ma, L. Cai, Biomaterials 2013, 34, 5236. [159] F. Yang, W. Song, C. Zhang, C. Min, H. Fang, L. Du, P. Wu, W. Zheng, C. Li, S. Zhu, X. Yuan, Nanoscale 2018, 10, 8606. [160] A. De la Zerda, C. Zavaleta, S. Keren, S. Vaithilingam, S. Bodapati, Z. Liu, J. Levi, B. R. Smith, T. J. Ma, O. Oralkan, Z. Cheng, X. Chen, H. Dai, B. T. Khuri-Yakub, S. S. Gambhir, Nat. Nanotechnol. 2008, 3, 557. [161] A. de Zerda, S. Bodapati, R. Teed, S. Y. May, S. M. Tabakman, Z. Liu, B. T. Khuri-Yakub, X. Chen, H. Dai, S. S. Gambhir, ACS Nano 2012, 6, 4694. [162] Y. Liu, R. Cheng, L. Liao, H. Zhou, J. Bai, G. Liu, L. Liu, Y. Huang, X. Duan, Nat. Commun. 2011, 2, 579. [163] T. J. Echtermeyer, L. Britnell, P. K. Jasnos, A. Lombardo, R. V. Gorbachev, A. N. Grigorenko, A. K. Geim, A. C. Ferrari, K. S. Novoselov, Nat. Commun. 2011, 2, 458. [164] P. Wang, O. Liang, W. Zhang, T. Schroeder, Y. H. Xie, Adv. Mater. 2013, 25, 4918. [165] A. de la Zerda, Z. Liu, S. Bodapati, R. Teed, S. Vaithilingam, B. T. Khuri-Yakub, X. Chen, H. Dai, S. S. Gambhir, Nano Lett. 2010, 10, 2168. [166] M. Swierczewska, K. Y. Choi, E. L. Mertz, X. Huang, F. Zhang, L. Zhu, H. Y. Yoon, J. H. Park, A. Bhirde, S. Lee, X. Chen, Nano Lett. 2012, 12, 3613. [167] X. Wang, C. Wang, L. Cheng, S. T. Lee, Z. Liu, J. Am. Chem. Soc. 2012, 134, 7414. [168] L. Meng, W. Xia, L. Liu, L. Niu, Q. Lu, ACS Appl. Mater. Interfaces 2014, 6, 4989. [169] J. Song, F. Wang, X. Yang, B. Ning, M. G. Harp, S. H. Culp, S. Hu, P. Huang, L. Nie, J. Chen, X. Chen, J. Am. Chem. Soc. 2016, 138, 7005. [170] J. W. Kim, E. I. Galanzha, E. V. Shashkov, H. M. Moon, V. P. Zharov, Nat. Nanotechnol. 2009, 4, 688. [171] L. Meng, L. Niu, L. Li, Q. Lu, Z. Fei, P. J. Dyson, Chemistry 2012, 18, 13314. [172] L. Nie, P. Huang, W. Li, X. Yan, A. Jin, Z. Wang, Y. Tang, S. Wang, X. Zhang, G. Niu, X. Chen, ACS Nano 2014, 8, 12141. [173] G. Yu, J. Yang, X. Fu, Z. Wang, L. Shao, Z. Mao, Y. Liu, Z. Yang, F. Zhang, W. Fan, J. Song, Z. Zhou, C. Gao, F. Huang, X. Chen, Mater. Horiz. 2018, 5, 429. [174] A. Bianco, Z. Liu, Carbon 2016, 97, 124. [175] D. K. Lim, A. Barhoumi, R. G. Wylie, G. Reznor, R. S. Langer, D. S. Kohane, Nano Lett. 2013, 13, 4075. [176] H. Moon, D. Kumar, H. Kim, C. Sim, J. H. Chang, J. M. Kim,\nH. Kim, D. K. Lim, ACS Nano 2015, 9, 2711.\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (29 of 31)\nAdv. Mater. 2019, 31, 1805875\n[177] J. Song, X. Yang, O. Jacobson, L. Lin, P. Huang, G. Nie, Q. Ma, X. Chen, ACS Nano 2015, 9, 9199. [178] L.-S. Lin, X. Yang, G. Niu, J. Song, H.-H. Yang, X. Chen, Nanoscale 2016, 8, 2116. [179] Y. Lin, Y. Wu, R. Wang, G. Tao, P.-F. Luo, X. Lin, G. Huang, J. Li, H.-H. Yang, Chem. Commun. 2018, 54, 8579. [180] X. Ji, N. Kong, J. Wang, W. Li, Y. Xiao, S. T. Gan, Y. Zhang, Y. Li, X. Song, Q. Xiong, S. Shi, Z. Li, W. Tao, H. Zhang, L. Mei, J. Shi, Adv. Mater. 2018, 30, 1803031. [181] X. Qian, Z. Gu, Yu. Chen, Mater. Horiz. 2017, 4, 800. [182] Z. Sun, Y. Zhao, Z. Li, H. Cui, Y. Zhou, W. Li, W. Tao, H. Zhang,\nH. Wang, P. K. Chu, X.-F. Yu, Small 2017, 13, 1602896. [183] H. Lin, Y. Wang, S. Gao, Y. Chen, J. Shi, Adv. Mater. 2018, 30,\n1703284. [184] J. Chen, X. Li, X. Liu, H. Yan, Z. Xie, Z. Sheng, X. Gong, L. Wang,\nX. Liu, P. Zhang, H. Zheng, L. Song, C. Liu, Biomater. Sci. 2018, 6, 1503. [185] Z. Li, Z. Li, L. Chen, Y. Hu, S. Hu, Z. Miao, Y. Sun, F. Besenbacher, M. Yu, Nano Res. 2018, 11, 2436. [186] Z.-H. Miao, L.-X. Lv, K. Li, P.-Y. Liu, Z. Li, H. Yang, Q. Zhao, M. Chang, L. Zhen, C.-Y. Xu, Small 2018, 14, 1703789. [187] Z. Guo, S. Zhu, Y. Yong, X. Zhang, X. Dong, J. Du, J. Xie, Q. Wang, Z. Gu, Y. Zhao, Adv. Mater. 2017, 29, 1704136. [188] Y. Li, Y. Sun, T. Cao, Q. Su, Z. Li, M. Huang, R. Ouyang, H. Chang, S. Zhang, Y. Miao, Nanoscale 2017, 9, 14364. [189] Y. Chen, L. Cheng, Z. Dong, Y. Chao, H. Lei, H. Zhao, J. Wang, Z. Liu, Angew. Chem., Int. Ed. 2017, 56, 12991. [190] M. Wang, K. Deng, W. Lu, X. Deng, K. Li, Y. Shi, B. Ding, Z. Cheng, B. Xing, G. Han, Z. Hou, J. Lin, Adv. Mater. 2018, 30, 1706747. [191] L. Dong, G. Ji, Y. Liu, X. Xu, P. Lei, K. Du, S. Song, J. Feng, H. Zhang, Nanoscale 2018, 10, 825. [192] C. Dai, Y. Chen, X. Jing, L. Xiang, D. Yang, H. Lin, Z. Liu, X. Han, R. Wu, ACS Nano 2017, 11, 12696. [193] C. Dai, H. Lin, G. Xu, Z. Liu, R. Wu, Y. Chen, Chem. Mater. 2017, 29, 8637. [194] X. Deng, K. Li, X. Cai, B. Liu, Y. Wei, K. Deng, Z. Xie, Z. Wu, P. Ma, Z. Hou, Z. Cheng, J. Lin, Adv. Mater. 2017, 29, 1701266. [195] L.-S. Lin, Z.-X. Cong, J.-B. Cao, K.-M. Ke, Q.-L. Peng, J. Gao, H.-H. Yang, G. Liu, X. Chen, ACS Nano 2014, 8, 3876. [196] J. P. Thawani, A. Amirshaghaghi, L. Yan, J. M. Stein, J. Liu, A. Tsourkas, Small 2017, 13, 1701300. [197] G. Song, J. Hao, C. Liang, T. Liu, M. Gao, L. Cheng, J. Hu, Z. Liu, Angew. Chem., Int. Ed. 2016, 55, 2122. [198] J. F. Lovell, C. S. Jin, E. Huynh, H. Jin, C. Kim, J. L. Rubinstein, W. C. W. Chan, W. Cao, L. V. Wang, G. Zheng, Nat. Mater. 2011, 10, 324. [199] E. Huynh, B. Y. C. Leung, B. L. Helfield, M. Shakiba, J.-A. Gandier, C. S. Jin, E. R. Master, B. C. Wilson, D. E. Goertz, G. Zheng, Nat. Nanotechnol. 2015, 10, 325. [200] J. Rieffel, F. Chen, J. Kim, G. Chen, W. Shao, S. Shao, U. Chitgupi, R. Hernandez, S. A. Graves, R. J. Nickles, P. N. Prasad, C. Kim, W. Cai, J. F. Lovell, Adv. Mater. 2015, 27, 1785. [201] J. A. Viator, J. Komadina, L. O. Svaasand, G. Aguilar, B. Choi, J. S. Nelson, J. Invest. Dermatol. 2004, 122, 1432. [202] A. Krumholz, S. J. VanVickle-Chavez, J. Yao, T. P. Fleming, W. E. Gillanders, L. V. Wang, J. Biomed. Opt. 2011, 16, 080503. [203] R. J. Paproski, A. Heinmiller, K. Wachowicz, R. J. Zemp, Sci. Rep. 2014, 4, 5329. [204] Y. Liu, S. Wang, Y. Ma, J. Lin, H. Y. Wang, Y. Gu, X. Chen, P. Huang, Adv. Mater. 2017, 29, 1606129. [205] C. Yin, Y. Tang, X. Li, Z. Yang, J. Li, X. Li, W. Huang, Q. Fan, Small 2018, 14, 1703400. [206] Q. Fan, K. Cheng, Z. Yang, R. Zhang, M. Yang, X. Hu, X. Ma, L. Bu, X. Lu, X. Xiong, W. Huang, H. Zhao, Z. Cheng, Adv. Mater. 2015, 27, 843.\n[207] C. Cui, Z. Yang, X. Hu, J. Wu, K. Shou, H. Ma, C. Jian, Y. Zhao, B. Qi, X. Hu, A. Yu, Q. Fan, ACS Nano 2017, 11, 3298. [208] X. Hu, F. Lu, L. Chen, Y. Tang, W. Hu, X. Lu, Y. Ji, Z. Yang, W. Zhang, C. Yin, W. Huang, Q. Fan, ACS Appl. Mater. Interfaces 2017, 9, 30458. [209] Z. Yang, J. Song, Y. Dai, J. Chen, F. Wang, L. Lin, Y. Liu, F. Zhang, G. Yu, Z. Zhou, W. Fan, W. Huang, Q. Fan, X. Chen, Theranostics 2017, 7, 2177. [210] Z. Yang, R. Tian, J. Wu, Q. Fan, B. C. Yung, G. Niu, O. Jacobson, Z. Wang, G. Liu, G. Yu, W. Huang, J. Song, X. Chen, ACS Nano 2017, 11, 4247. [211] P. Sun, X. Wang, G. Wang, W. Deng, Q. Shen, R. Jiang, W. Wang, Q. Fan, W. Huang, J. Mater. Chem. B 2018, 6, 3395. [212] W. Tang, Z. Yang, S. Wang, Z. Wang, J. Song, G. Yu, W. Fan, Y. Dai, J. Wang, L. Shan, G. Niu, Q. Fan, X. Chen, ACS Nano 2018, 12, 2610. [213] Z. Yang, Y. Dai, C. Yin, Q. Fan, W. Zhang, J. Song, G. Yu, W. Tang, W. Fan, B. C. Yung, J. Li, X. Li, X. Li, Y. Tang, W. Huang, J. Song, X. Chen, Adv. Mater. 2018, 30, 1707509. [214] G. Yu, Z. Yang, X. Fu, B. C. Yung, J. Yang, Z. Mao, L. Shao, B. Hua, Y. Liu, F. Zhang, Q. Fan, S. Wang, O. Jacobson, A. Jin, C. Gao, X. Tang, F. Huang, X. Chen, Nat. Commun. 2018, 9, 766. [215] P. Sun, P. Yuan, G. Wang, W. Deng, S. Tian, C. Wang, X. Lu, W. Huang, Q. Fan, Biomacromolecules 2017, 18, 3375. [216] J. F. Lovell, C. S. Jin, E. Huynh, H. Jin, C. Kim, J. L. Rubinstein, W. C. Chan, W. Cao, L. V. Wang, G. Zheng, Nat. Mater. 2011, 10, 324. [217] E. Huynh, J. F. Lovell, B. L. Helfield, M. Jeon, C. Kim, D. E. Goertz, B. C. Wilson, G. Zheng, J. Am. Chem. Soc. 2012, 134, 16464. [218] E. Huynh, B. Y. Leung, B. L. Helfeld, M. Shakiba, J. A. Gandier, C. S. Jin, E. R. Master, B. C. Wilson, D. E. Goertz, G. Zheng, Nat. Nanotechnol. 2015, 10, 325. [219] R. J. Paproski, A. Forbrich, E. Huynh, J. Chen, J. D. Lewis, G. Zheng, R. J. Zemp, Small 2016, 12, 371. [220] F. Song, X. Peng, E. Lu, R. Zhang, X. Chen, B. Song, J. Photochem. Photobiol., A 2004, 168, 53. [221] J. Kang, D. Kim, J. Wang, Y. Han, J. M. Zuidema, A. Hariri, J. H. Park, J. V. Jokerst, M. J. Sailor, Adv. Mater. 2018, 30, 1800512. [222] Q. Chen, X. Liu, J. Chen, J. Zeng, Z. Cheng, Z. Liu, Adv. Mater. 2015, 27, 6820. [223] Y. Zhang, M. Jeon, L. J. Rich, H. Hong, J. Geng, Y. Zhang, S. Shi, T. E. Barnhart, P. Alexandridis, J. D. Huizinga, M. Seshadri, W. Cai, C. Kim, J. F. Lovell, Nat. Nanotechnol. 2014, 9, 631. [224] C. Xie, X. Zhen, Y. Lyu, K. Y. Pu, Adv. Mater. 2017, 29, 1703693. [225] L. Tang, F. Zhang, F. Yu, W. Sun, M. Song, X. Chen, X. Zhang, X. Sun, Biomaterials 2017, 129, 28. [226] S. Sreejith, J. Joseph, M. Lin, N. V. Menon, P. Borah, H. J. Ng, Y. X. Loong, S. Y. Kang, W.-K. Yu, Y. Zhao, ACS Nano 2015, 9, 5695. [227] T. Kim, J. E. Lemaster, F. Chen, J. Li, J. V. Jokerst, ACS Nano 2017, 11, 9022. [228] Z. Qin, Y. Li, N. Gu, Adv. Healthcare Mater. 2018, e1800347. [229] C. Cui, Z. Yang, X. Hu, J. Wu, K. Shou, H. Ma, C. Jian, Y. Zhao, B. Qi, A. Yu, Q. Fan, ACS Nano 2017, 11, 3298. [230] Z. Yang, Y. Dai, C. Yin, Q. Fan, W. Zhang, J. Song, G. Yu, W. Tang,\nW. Fan, B. C. Yung, J. Li, X. Li, Y. Tang, W. Huang, X. Chen, Adv. Mater. 2018, 30, 1707509. [231] X. Zheng, L. Wang, S. Liu, W. Zhang, F. Liu, Z. Xie, Adv. Funct. Mater. 2018, 28, 1706507. [232] J. Yang, S. Zhai, H. Qin, H. Yan, D. Xing, X. Hu, Biomaterials 2018, 176, 1. [233] Y. Jin, X. Yang, J. Tian, Nanoscale 2018, 10, 9594. [234] L. Chen, Yu. Ji, X. Hu, C. Cui, H. Liu, Y. Tang, B. Qi, Y. Niu, X. Hu, A. Yu, Q. Fan, Nanoscale 2018, 10, 13471. [235] J. Qi, C. Chen, X. Zhang, X. Hu, S. Ji, R. T. K. Kwok, J. W. Y. Lam,\nD. Ding, B. Z. Tang, Nat. Commun. 2018, 9, 1848.\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (30 of 31)\nAdv. Mater. 2019, 31, 1805875\n[236] Z.-H. Miao, K. Li, P.-Y. Liu, Z. Li, H. Yang, Q. Zhao, M. Chang, Q. Yang, L. Zhen, C.-Y. Xu, Adv. Healthcare Mater. 2018, 7, 1701202. [237] T. Liu, M. Zhang, W. Liu, X. Zeng, X. Song, X. Yang, X. Zhang, J. Feng, ACS Nano 2018, 12, 3917. [238] K. Pu, A. J. Shuhendler, J. V. Jokerst, J. Mei, S. S. Gambhir, Z. Bao, J. Rao, Nat. Nanotechnol. 2014, 9, 233. [239] K. Pu, J. Mei, J. V. Jokerst, G. Hong, A. L. Antaris, N. Chattopadhyay, A. J. Shuhendler, T. Kurosawa, Y. Zhou, S. S. Gambhir, Z. Bao, J. Rao, Adv. Mater. 2015, 27, 5184. [240] Y. Lyu, Y. Fang, Q. Miao, X. Zhen, D. Ding, K. Pu, ACS Nano 2016, 10, 4472. [241] Q. Miao, Y. Lyu, D. Ding, K. Pu, Adv. Mater. 2016, 28, 3662. [242] Y. Lyu, X. Zhen, Y. Miao, K. Pu, ACS Nano 2017, 11, 358. [243] C. Xie, P. K. Upputuri, X. Zhen, M. Pramanik, K. Pu, Biomaterials 2017, 119, 1. [244] C. Xie, X. Zhen, Q. Lei, R. Ni, K. Pu, Adv. Funct. Mater. 2017, 27, 1605397. [245] C. Yin, X. Zhen, H. Zhao, Y. Tang, Y. Ji, Y. Lyu, Q. Fan, W. Huang, K. Pu, ACS Appl. Mater. Interfaces 2017, 9, 12332. [246] J. Zhang, X. Zhen, P. K. Upputuri, M. Pramanik, P. Chen, K. Pu, Adv. Mater. 2017, 29, 1604764. [247] C. Yin, X. Zhen, Q. Fan, W. Huang, K. Pu, ACS Nano 2017, 11, 4174. [248] Y. Lyu, J. Zeng, Y. Jiang, X. Zhen, T. Wang, S. Qiu, X. Lou, M. Gao, K. Pu, ACS Nano 2018, 12, 1801. [249] K. Pu, J. G. Mei, J. V. Jokerst, G. S. Hong, A. L. Antaris,\nN. Chattopadhyay, A. J. Shuhendler, T. Kurosawa, Y. Zhou, S. S. Gambhir, Z. N. Bao, J. H. Rao, Adv. Mater. 2015, 27, 5184.\n[250] Z. L. Tyrrell, Y. Shen, M. Radosz, Prog. Polym. Sci. 2010, 35, 1128. [251] X. Zhen, C. Zhang, C. Xie, Q. Miao, K. L. Lim, K. Pu, ACS Nano 2016, 10, 6400. [252] N. Kang, M. E. Perron, R. E. Prud’homme, Y. B. Zhang, G. Gaucher, J. C. Leroux, Nano Lett. 2005, 5, 315. [253] C. J. Rijcken, C. J. Snel, R. M. Schiffelers, C. F. van Nostrum, W. E. Hennink, Biomaterials 2007, 28, 5581. [254] C. Xie, X. Zhen, Q. L. Lei, R. Ni, K. Y. Pu, Adv. Funct. Mater. 2017, 27, 1605397. [255] C. Yin, X. Zhen, Q. L. Fan, W. Huang, K. Y. Pu, ACS Nano 2017, 11, 4174. [256] S. Mecking, Angew. Chem., Int. Ed. 2004, 43, 1078. [257] Y. Lyu, J. F. Zeng, Y. Y. Jiang, X. Zhen, T. Wang, S. S. Qiu, X. Lou, M. Y. Gao, K. Y. Pu, ACS Nano 2018, 12, 1801. [258] C. Tian, Z. Xie, M. L. Fabiilli, S. Liu, C. Wang, Q. Cheng, X. Wang, Biomed. Opt. Express 2015, 6, 2923. [259] J. Yao, A. A. Kaberniuk, L. Li, D. M. Shcherbakova, R. Zhang,\nL. Wang, G. Li, V. V. Verkhusha, L. V. Wang, Nat. Methods. 2016, 13, 67.\n[260] L. Wang, C. Zhang, L. V. Wang, Phys. Rev. Lett. 2014, 113, 174301. [261] F. Gao, X. Feng, R. Zhang, S. Liu, R. Ding, R. Kishor, Y. Zheng, Sci. Rep. 2017, 7, 626. [262] F. Gao, R. Kishor, X. Feng, S. Liu, R. Ding, R. Zhang, Y. Zheng, Photoacoustics 2017, 7, 1. [263] F. Gao, X. Feng, Y. Zheng, J. Opt. 2016, 18, 074006. [264] D. A. Nedosekin, E. I. Galanzha, E. Dervishi, A. S. Biris, V. P. Zharov, Small 2014, 10, 135. [265] Z. Zhang, Y. Shi, S. Yang, D. Xing, Opt. Lett. 2018, 43, 2336. [266] C. Tian, Z. Xie, M. L. Fabiilli, X. Wang, Opt. Lett. 2015, 40, 2253. [267] F. Gao, L. Bai, X. Feng, H. P. Tham, R. Zhang, Y. Zhang, S. Liu, L. Zhao, Y. Zheng, Y. Zhao, Small 2016, 12, 5239. [268] F. Gao, L. Bai, S. Liu, R. Zhang, J. Zhang, X. Feng, Y. Zheng, Y. Zhao, Nanoscale 2017, 9, 79. [269] H. Li, P. Zhang, L. P. Smaga, R. A. Hoffman, J. Chan, J. Am. Chem.\nSoc. 2015, 137, 15628.\n[270] Y. Huang, F. Li, G. Ma, W. Yang, X. Zhang, J. Lin, Y. Luo, P. Huang, Talanta 2018, 187, 65. [271] S. Roberts, M. Seeger, Y. Jiang, A. Mishra, F. Sigmund, A. Stelzl, A. Lauri, P. Symvoulidis, H. Rolbieski, M. Preller, X. L. Dean-Ben, D. Razansky, T. Orschmann, S. C. Desbordes, P. Vetschera, T. Bach, V. Ntziachristos, G. G. Westmeyer, J. Am. Chem. Soc. 2018, 140, 2718. [272] A. Mishra, Y. Jiang, S. Roberts, V. Ntziachristos, G. G. Westmeyer, Anal. Chem. 2016, 88, 10785. [273] K. J. Cash, C. Li, J. Xia, L. V. Wang, H. A. Clark, ACS Nano 2015, 9, 1692. [274] H. J. Adrogué, N. E. Madias, N. Engl. J. Med. 1998, 338, 26. [275] S. Grinstein, C. J. Swallow, O. D. Rotstein, Clin. Biochem. 1991, 24, 241. [276] J. Jo, C. H. Lee, R. Kopelman, X. Wang, Nat. Commun. 2017, 8, 471. [277] Q. Chen, X. Liu, J. Zeng, Z. Cheng, Z. Liu, Biomaterials 2016, 98, 23. [278] Q. Q. Miao, Y. Lyu, D. Ding, K. Y. Pu, Adv. Mater. 2016, 28, 3662. [279] M. R. Chatni, J. Yao, A. Danielli, C. P. Favazza, K. I. Maslov, L. V. Wang, J. Biomed. Opt. 2011, 16, 100503. [280] K.-Y. Ju, J. Kang, J. Pyo, J. Lim, J. H. Chang, J.-K. Lee, Nanoscale 2016, 8, 14448. [281] S. Shi, Y. Liu, Y. Chen, Z. Zhang, Y. Ding, Z. Wu, J. Yin, L. Nie,\nTheranostics 2016, 6, 2170. [282] C. W. Kimbrough, A. Khanal, M. Zeiderman, B. R. Khanal,\nN. C. Burton, K. M. McMasters, S. M. Vickers, W. E. Grizzle, L. R. McNally, Clin. Cancer Res. 2015, 21, 4576. [283] S. Guha, G. K. Shaw, T. M. Mitcham, R. R. Bouchard, B. D. Smith, Chem. Commun. 2016, 52, 120. [284] T. D. Horvath, G. Kim, R. Kopelman, S. Ashkenazi, Analyst 2008, 133, 747. [285] A. Ray, H. K. Yoon, Y. E. K. Lee, R. Kopelman, X. Wang, Analyst 2013, 138, 3126. [286] Q. Tang, W. Xiao, C. Huang, W. Si, J. Shao, W. Huang, P. Chen, Q. Zhang, X. Dong, Chem. Mater. 2017, 29, 5216. [287] A. Barzilai, G. Rotman, Y. Shiloh, DNA Repair 2002, 1, 3. [288] X. Chen, X. Tian, I. Shin, J. Yoon, Chem. Soc. Rev. 2011, 40, 4783. [289] L. Khandrika, B. Kumar, S. Koul, P. Maroni, H. K. Koul, Cancer Lett. 2009, 282, 125. [290] C. Sand, S. L. M. Peters, M. Pfaffendorf, P. A. van Zwieten, Clin. Exp. Pharmacol. Physiol. 2003, 30, 249. [291] A. Daugherty, J. L. Dunn, D. L. Rateri, J. W. Heinecke, J. Clin. Invest. 1994, 94, 437. [292] S. Hammerschmidt, N. Buchler, H. Wahn, Chest 2002, 121, 573. [293] S. Hammerschmidt, H. Wahn, Biochim. Biophys. Acta, Mol. Basis Dis. 2004, 1690, 258. [294] M. J. Steinbeck, L. J. Nesti, P. F. Sharkey, J. Parvizi, J. Bone Miner. Res. 2006, 21, S144. [295] M. J. Steinbeck, L. J. Nesti, P. F. Sharkey, J. Parvizi, J. Orthop. Res. 2007, 25, 1128. [296] D. I. Pattison, M. J. Davies, Chem. Res. Toxicol. 2001, 14, 1453. [297] B. Pan, H. Ren, X. Lv, Y. Zhao, B. Yu, Y. He, Y. Ma, C. Niu, J. Kong,\nF. Yu, W. Sun, Y. Zhang, B. Willard, L. Zheng, J. Transl. Med. 2012, 10, 65.\n[298] J. Bai, X. Jiang, Anal. Chem. 2013, 85, 8095. [299] C. C. Winterbourn, Nat. Chem. Biol. 2008, 4, 278. [300] T. Finkel, M. Serrano, M. A. Blasco, Nature 2007, 448, 767. [301] G. C. Van de Bittner, E. A. Dubikovskaya, C. R. Bertozzi, C. J. Chang, Proc. Natl. Acad. Sci. USA 2010, 107, 21316. [302] Q. Chen, C. Liang, X. Sun, J. Chen, Z. Yang, H. Zhao, L. Feng, Z. Liu, Proc. Natl. Acad. Sci. USA 2017, 114, 5343. [303] P. F. Bove, A. van der Vliet, Free Radicals Biol. Med. 2006, 41, 515. [304] X. Qin, F. Li, Y. Zhang, G. Ma, T. Feng, Y. Luo, P. Huang, J. Lin,\nAnal. Chem. 2018, 90, 9381.\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805875 (31 of 31)\nAdv. Mater. 2019, 31, 1805875\n[305] J. Zhang, X. Zhen, J. Zeng, K. Pu, Anal. Chem. 2018, 90, 9301. [306] C. J. Reinhardt, E. Y. Zhou, M. D. Jorgensen, G. Partipilo, J. Chan, J. Am. Chem. Soc. 2018, 140, 1011. [307] E. Y. Zhou, H. J. Knox, C. J. Reinhardt, G. Partipilo, M. J. Nilges, J. Chan, J. Am. Chem. Soc. 2018, 140, 11686. [308] A. Baruch, D. A. Jeffery, M. Bogyo, Trends Cell Biol. 2004, 14, 29. [309] R. Q. Yan, D. J. Ye, Sci. Bull. 2016, 61, 1672. [310] A. Dragulescu-Andrasi, S. R. Kothapalli, G. A. Tikhomirov, J. Rao, S. S. Gambhir, J. Am. Chem. Soc. 2013, 135, 11015. [311] J. Zhang, L. P. Smaga, N. S. R. Satyavolu, J. Chan, Y. Lu, J. Am. Chem. Soc. 2017, 139, 17225. [312] Y. S. Chen, W. Frey, C. Walker, S. Aglyamov, S. Emelianov, J. Biophotonics 2013, 6, 534. [313] K. K. Ng, M. Shakiba, E. Huynh, R. A. Weersink, A. Roxin, B. C. Wilson, G. Zheng, ACS Nano 2014, 8, 8363. [314] Y. S. Chen, S. J. Yoon, W. Frey, M. Dockery, S. Emelianov, Nat. Commun. 2017, 8, 15782. [315] B. Nath, G. Szabo, Hepatology 2012, 55, 622. [316] J. I. Weitz, J. Byrne, G. P. Clagett, M. E. Farkouh, J. M. Porter,\nD. L. Sackett, D. E. Strandness, L. M. Taylor, Circulation 1996, 94, 3026. [317] E. B. Rankin, A. J. Giaccia, Science 2016, 352, 175. [318] J. B. West, N. Engl. J. Med. 2017, 376, 1965. [319] H. J. Knox, J. Hedhli, T. W. Kim, K. Khalili, L. W. Dobrucki, J. Chan,\nNat. Commun. 2017, 8, 1794. [320] H. J. Knox, T. W. Kim, Z. Zhu, J. Chan, ACS Chem. Biol. 2018, 13,\n1838. [321] J. N. Liu, W. Bu, J. Shi, Chem. Rev. 2017, 117, 6160. [322] K. Y. Zhang, P. Gao, G. Sun, T. Zhang, X. Li, S. Liu, Q. Zhao, K. K. Lo, W. Huang, J. Am. Chem. Soc. 2018, 140, 7827. [323] T. Ma, J. Zheng, T. Zhang, D. Xing, Nanoscale 2018, 10, 13462. [324] B. Shi, X. Gu, Q. Fei, C. Zhao, Chem. Sci. 2017, 8, 2150. [325] L. Li, A. A. Shemetov, M. Baloban, P. Hu, L. Zhu,\nD. M. Shcherbakova, R. Zhang, J. Shi, J. Yao, L. V. Wang, V. V. Verkhusha, Nat. Commun. 2018, 9, 2734. [326] G. P. Luke, J. N. Myers, S. Y. Emelianov, K. V. Sokolov, Cancer Res. 2014, 74, 5397. [327] J. Kang, J. H. Chang, S. M. Kim, H. J. Lee, H. Kim, B. C. Wilson, T.-K. Song, Sci. Rep. 2017, 7, 45008. [328] L. Yang, J. Cheng, Y. Chen, S. Yu, F. Liu, Y. Sun, Y. Chen, H. Ran, Sci. Rep. 2017, 7, 45213. [329] A. Garcia-Uribe, T. N. Erpelding, A. Krumholz, H. Ke, K. Maslov, C. Appleton, J. A. Margenthaler, L. V. Wang, Sci. Rep. 2015, 5, 15748. [330] X. Cai, X. Liu, L.-D. Liao, A. Bandla, J. M. Ling, Y.-H. Liu, N. Thakor, G. C. Bazan, B. Liu, Small 2016, 12, 4873. [331] F. Cao, Y. Guo, Y. Li, S. Tang, Y. Yang, H. Yang, L. Xiong, Adv. Funct. Mater. 2018, 28, 1707174.\n[332] Y. Y. Jiang, P. K. Upputuri, C. Xie, Y. Lyu, L. L. Zhang, Q. H. Xiong, M. Pramanik, K. Y. Pu, Nano Lett. 2017, 17, 4964. [333] K. V. Kong, L. D. Liao, Z. Lam, N. V. Thakor, W. K. Leong, M. Olivo, Chem. Commun. 2014, 50, 2601. [334] P. Schoenhagen, D. G. Vince, J. Am. Coll. Cardiol. 2014, 64, 391. [335] C. Wu, Y. Zhang, Z. Li, C. Li, Q. Wang, Nanoscale 2016, 8, 12531. [336] J. Zhang, S. Yang, X. Ji, Q. Zhou, D. Xing, J. Am. Coll. Cardiol. 2014, 64, 385. [337] D. Pan, M. Pramanik, A. Senpan, X. Yang, K. H. Song, M. J. Scott,\nH. Zhang, P. J. Gaffney, S. A. Wickline, L. V. Wang, G. M. Lanza, Angew. Chem., Int. Ed. 2009, 48, 4170.\n[338] K. Cheng, H. Chen, C. H. Jenkins, G. Zhang, W. Zhao, Z. Zhang, F. Han, J. Fung, M. Yang, Y. Jiang, L. Xing, Z. Cheng, ACS Nano 2017, 11, 12276. [339] E. Jung, C. Kang, J. Lee, D. Yoo, D. W. Hwang, D. Kim, S. C. Park, S. K. Lim, C. Song, D. Lee, ACS Nano 2018, 12, 392. [340] J. Zhang, H. Chen, T. Zhou, L. Wang, D. Gao, X. Zhang, Y. Liu, C. Wu, Z. Yuan, Nano Res. 2016, 10, 64. [341] L. J. Rich, M. Seshadri, Radiology 2015, 275, 110. [342] M. Nasiriavanaki, J. Xia, H. Wan, A. Q. Bauer, J. P. Culver, L. V. Wang, Proc. Natl. Acad. Sci. USA 2014, 111, 21. [343] J. Yao, L. Wang, J.-M. Yang, K. I. Maslov, T. T. W. Wong, L. Li, C.-H. Huang, J. Zou, L. V. Wang, Nat. Methods 2015, 12, 407. [344] D. Wang, Y. Wu, J. Xia, Neurophotonics 2016, 3, 010901. [345] B. Guo, Z. Sheng, Kenry, D. Hu, X. Lin, S. Xu, C. Liu, H. Zheng, B. Liu, Mater. Horiz. 2017, 4, 1151. [346] J. Kang, D. Kim, J. Wang, Y. Han, J. M. Zuidema, A. Hariri, J.-H. Park, J. V. Jokerst, M. J. Sailor, Adv. Mater. 2018, 30, 1800512. [347] Z. Sheng, B. Guo, D. Hu, S. Xu, W. Wu, W. H. Liew, K. Yao,\nJ. Jiang, C. Liu, H. Zheng, B. Liu, Adv. Mater. 2018, 30, 1800766.\n[348] M. Wu, W. Chen, Y. Chen, H. Zhang, C. Liu, Z. Deng, Z. Sheng, J. Chen, X. Liu, F. Yan, H. Zheng, Adv. Sci. 2018, 5, 1700474. [349] Y. Wang, X. Xie, X. Wang, G. Ku, K. L. Gill, D. P. O’Neal, G. Stoica, L. V. Wang, Nano Lett. 2004, 4, 1689. [350] W. Li, R. Chen, J. Lv, H. Wang, Y. Liu, Y. Peng, Z. Qian, G. Fu, L. Nie, Adv. Sci. 2018, 5, 1700277. [351] J. Liu, X. Cai, H. C. Pan, A. Bandla, C. K. Chuan, S. Wang, N. Thakor, L. D. Liao, B. Liu, Small 2018, 14, e1703732. [352] B. Rao, R. Zhang, L. Li, J.-Y. Shao, L. V. Wang, Sci. Rep. 2017, 7, 2560. [353] M. F. Kircher, A. L. Zerda, J. V. Jokerst, C. L. Zavaleta, P. J. Kempen, E. Mittra, K. Pitter, R. Huang, C. Campos, F. Habte, R. Sinclair, C. W. Brennan, I. K. Mellinghoff, E. C. Holland, S. S. Gambhir, Nat. Med. 2012, 18, 829. [354] T. T. W. Wong, R. Zhang, C. Zhang, H. C. Hsu, K. I. Maslov, L. Wang, J. Shi, R. Chen, K. K. Shung, Q. Zhou, L. V. Wang, Nat. Commun. 2017, 8, 1386."
    } ],
    "references" : [ {
      "title" : "Phys",
      "author" : [ "F.A. McDonald", "G.C. Wetsel", "J. Appl" ],
      "venue" : "1978, 49,",
      "citeRegEx" : "7",
      "shortCiteRegEx" : null,
      "year" : 2313
    }, {
      "title" : "Bio-Med",
      "author" : [ "J. Xia", "L.V. Wang", "IEEE Trans" ],
      "venue" : "Eng. 2014, 61,",
      "citeRegEx" : "21",
      "shortCiteRegEx" : null,
      "year" : 1380
    }, {
      "title" : "Nanotechnol",
      "author" : [ "X. Wang", "L. Zhang", "J. Wang", "X. Liu", "P. Lv", "J. Zeng", "G. Liu", "J. Biomed" ],
      "venue" : "2018, 14,",
      "citeRegEx" : "120",
      "shortCiteRegEx" : null,
      "year" : 1448
    }, {
      "title" : "Dermatol",
      "author" : [ "J.A. Viator", "J. Komadina", "L.O. Svaasand", "G. Aguilar", "B. Choi", "J.S. Nelson", "J. Invest" ],
      "venue" : "2004, 122,",
      "citeRegEx" : "201",
      "shortCiteRegEx" : null,
      "year" : 1432
    }, {
      "title" : "Chem",
      "author" : [ "S. Roberts", "M. Seeger", "Y. Jiang", "A. Mishra", "F. Sigmund", "A. Stelzl", "A. Lauri", "P. Symvoulidis", "H. Rolbieski", "M. Preller", "X.L. Dean-Ben", "D. Razansky", "T. Orschmann", "S.C. Desbordes", "P. Vetschera", "T. Bach", "V. Ntziachristos", "G.G. Westmeyer", "J. Am" ],
      "venue" : "Soc. 2018, 140,",
      "citeRegEx" : "271",
      "shortCiteRegEx" : null,
      "year" : 2718
    }, {
      "title" : "Res",
      "author" : [ "M.J. Steinbeck", "L.J. Nesti", "P.F. Sharkey", "J. Parvizi", "J. Orthop" ],
      "venue" : "2007, 25,",
      "citeRegEx" : "295",
      "shortCiteRegEx" : null,
      "year" : 1128
    }, {
      "title" : "Chem",
      "author" : [ "C.J. Reinhardt", "E.Y. Zhou", "M.D. Jorgensen", "G. Partipilo", "J. Chan", "J. Am" ],
      "venue" : "Soc. 2018, 140,",
      "citeRegEx" : "306",
      "shortCiteRegEx" : null,
      "year" : 1011
    }, {
      "title" : "J",
      "author" : [ "J.B. West", "N. Engl" ],
      "venue" : "Med. 2017, 376,",
      "citeRegEx" : "318",
      "shortCiteRegEx" : null,
      "year" : 1965
    }, {
      "title" : "Biol",
      "author" : [ "H.J. Knox", "T.W. Kim", "Z. Zhu", "J. Chan", "ACS Chem" ],
      "venue" : "2018, 13,",
      "citeRegEx" : "320",
      "shortCiteRegEx" : null,
      "year" : 1838
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "[1–6] PA imaging exploits the PA effect[7] that was first reported by Alexander Graham Bell.",
      "startOffset" : 39,
      "endOffset" : 42
    }, {
      "referenceID" : 4,
      "context" : "PA imaging has been researched for sensing of heavy-metal ions, including copper (Cu2+),[269] methylmercury (MeHg+),[204] mercury(II),[270] calcium (Ca2+),[271,272] lithium (Li+),[273] and silver (Ag+).",
      "startOffset" : 155,
      "endOffset" : 164
    }, {
      "referenceID" : 4,
      "context" : "Recently, Westmeyer and co-workers developed a cellpermeable, highly selective, and sensitive PA imaging probe to sense Ca2+ content.[271] Using this probe, micromolar concentrations of Ca2+ led to a major blueshift in absorbance, causing a decrease in PA intensity.",
      "startOffset" : 133,
      "endOffset" : 138
    }, {
      "referenceID" : 5,
      "context" : "atheromatosis,[291] pneumopathy,[292,293] arthronosos,[294,295] neurodegeneration,[296] and tumors or cancer.",
      "startOffset" : 54,
      "endOffset" : 63
    }, {
      "referenceID" : 6,
      "context" : "[246] More recently, Chan and co-workers designed a set of acoustogenic probes for nitric oxide, termed APNOs, to sense NO in vivo[306] (Figure 11A).",
      "startOffset" : 130,
      "endOffset" : 135
    }, {
      "referenceID" : 6,
      "context" : "(A–G) Reproduced with permission.[306] Copyright 2018, American Chemical Society.",
      "startOffset" : 33,
      "endOffset" : 38
    }, {
      "referenceID" : 8,
      "context" : "(F–I) Reproduced with permission.[320] Copyright 2018, American Chemical Society.",
      "startOffset" : 33,
      "endOffset" : 38
    }, {
      "referenceID" : 8,
      "context" : "developed a hypoxia-responsive contrast agent, rHyP-1, with a high and low PA signal ratio for hypoxia and normoxia, respectively (Figure 14F).[320] In vitro PA imaging experiments of rHyP-1 showed the PA820nm/PA770nm ratio of the hypoxic condition to be 2-fold that under normoxic condition (Figure 14G).",
      "startOffset" : 143,
      "endOffset" : 148
    } ],
    "year" : 2019,
    "abstractText" : "DOI: 10.1002/adma.201805875 is caused by absorbed light energy, creating a broadband US wave that can be detected by a US transducer, converted to electric signals that are duly processed to get a PA image. PA imaging is a noninvasive imaging strategy that depends on the light-absorption coefficient of the imaged tissue. Since the PA signal varies according to the distribution of light absorption in biological tissue, therefore, PA imaging is similar to optical imaging, which achieves a high imaging contrast and is sensitive to the tissue characteristics. However, the carrier of the light-absorption information is not an optical signal but rather a US wave signal processed to obtain an image, with the merits of negligible scattering and dissipation in biological tissue. Therefore, PA imaging integrates the excellent contrast achieved in optical biomedical imaging with the deep penetrability of US imaging.[9] Thus, PA imaging can be used for the imaging of deeper tissue compared to other optical imaging technologies.[10,11] However, in comparison with US imaging, the light intensity and PA signal-to-noise ratio exhibit exponential attenuation with increasing tissue depth due to the strong laserscattering effect. To improve the PA-imaging contrast, resolution, and penetrability to tissue, externally injected PA-imaging contrast agents with high PA-imaging property in the tissue need to be developed.[12–15] In PA imaging based on contrast agents, the optical energy of a pulse laser is absorbed by PA contrast agents and subsequent converted to thermal energy with an increase of temperature. The instantaneous temperature rise results in thermoelastic expansion and subsequent ultrasonic emission that can be detected by employing a US transducer to reconstruct the PA image. Overall, the PA-imaging contrast mainly rests with optical absorbance and thermoacoustic conversion efficiency, since the generated PA signal amplitude is proportional to the light absorption and the thermoelastic performances of the absorbing agent. To further improve the PA imaging quality, various PA imaging modalities and agents have been explored to enhance the PA signal.[16–23] Commonly used contrast agents for PA imaging include endogenous chromophores, such as melanin,[24] oxyhemoglobin/deoxyhemoglobin,[25] lipids,[26] or collagen,[27] as well as exogenous contrast agents (henceforth referred to as contrast agents). Such agents are required to diagnose and treat diseases such as breast carcinoma or glioma, Photoacoustic (PA) imaging as a fast-developing imaging technique has great potential in biomedical and clinical applications. It is a noninvasive imaging modality that depends on the light-absorption coefficient of the imaged tissue and the injected PA-imaging contrast agents. Furthermore, PA imaging provides superb contrast, super spatial resolution, and high penetrability and sensitivity to tissue functional characteristics by detecting the acoustic wave to construct PA images. In recent years, a series of PA-imaging contrast agents are developed to improve the PA-imaging performance in biomedical applications. Here, recent progress of PA contrast agents and their biomedical applications are outlined. PA contrast agents are classified according to their components and function, and gold nanocrystals, gold-nanocrystal assembly, transition-metal chalcogenides/MXene-based nanomaterials, carbon-based nanomaterials, other inorganic imaging agents, small organic molecules, semiconducting polymer nanoparticles, and nonlinear PA-imaging contrast agents are discussed. The applications of PA contrast agents as biosensors (in the sensing of metal ions, pH, enzymes, temperature, hypoxia, reactive oxygen species, and reactive nitrogen species) and in bioimaging (lymph nodes, vasculature, tumors, and brain tissue) are discussed in detail. Finally, an outlook on the future research and investigation of PA-imaging contrast agents and their significance in biomedical research is presented. Photoacoustic Imaging",
    "creator" : "Adobe InDesign CS6 (Macintosh)"
  }
}